Regulation and functional analysis of the tumor suppressor gene product, p53 by MD MONOWARUL MOBIN SIDDIQUE
 REGULATION AND FUNCTIONAL ANALYSIS OF THE 

















A THESIS SUBMITTED  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF BIOCHEMISTRY 











I am very much grateful to my supervisor A/Prof Kanaga Sabapathy, for his constant 
guidance, active supervision, patience and support during the course of my study and 
research.  
 
I thank Dr Vikhanskaya and  Dr Lee Ming Kei for providing information in chapter 3.4. 
My sincere thanks goes to Mr Toh Wen Hong, Mr Muhammad Iqbal Dulloo, Ms Nam 
Shin Yuen, Ms Stephanie Soh, Ms Kelly Lum and Ms Phang Beng Hooi for their 
cooperation during my research.  
 
I would like to extend my gratitude to Prof Soo Khee Chee and A/Prof Hui Kam Man 
for providing me the opportunity to work in National Cancer Centre of Singapore.  
 
I am really grateful and indebted to my parents for all of their support that helped me to 
pursue my postgraduate study overseas.  
 
 







TABLE OF CONTENTS 
TITLE PAGE          I 
ACKNOWLEDGEMENT        II 
TABLE OF CONTENTS        III 
SUMMARY          X 
LIST OF FIGURES         XIV 
LIST OF PUBLICATIONS        XVI 
LIST OF SYMBOLS        XVII 
 
CAHPTER 1: INTRODUCTION 
1.1 p53, the tumour suppressor       1 
1.1.1 p53, the “Guardian of the Genome”     2 
1.1.2 p53 and DNA damage response pathway     3 
1.1.3 DNA repair and p53        3 
1.1.4 Cell cycle arrest by p53       5 
1.1.5 Role of p53 in DNA repair       6 
1.1.5.1 Gadd45  activation by p53       7 
1.1.5.2 p53R2 activation by p53       8 
1.2 Functions of different domains of p53     9 
1.3 Drug and chemotherapy resistance by mutant p53   11 
1.4 p53 polymorphism        12 
1.4.1 Distribution of p53 codon 72 polymorphism    13 
1.4.2 p53 polymorphism in human malignant diseases    13 
 III
1.4.2.1 Breast cancer         13 
1.4.2.2 Skin cancer         14 
1.4.2.3 Cervical cancer        14 
1.4.2.4 Gastric cancer        14 
1.4.2.5 Other cancers        15 
1.5 Functional difference of p53 polymorphs     16 
1.5.1 Implication of p53 polymorphism in drug sensitivity along with 16 
mutation 
1.5.2 p53 polymorphism and breast tumour     18 
1.5.3 p53 and melanin synthesis       19 
1.5.4 Nucleotide excision repair by p53      22 
1.5.5 p53’s role in ecological adaptation      23 
 
CHAPTER 2: MATERIAL AND METHODS 
2.1 Tissue culture        24 
2.2 Transfection         24 
2.3 Extraction of DNA and RNA      25 
2.3.1 Extraction of genomic DNA from blood     25 
2.3.2 Extraction of genomic DNA from tissue     25 
2.3.3 Extraction of genomic DNA from cultured cell    25 
2.3.4 Extraction of RNA from cultured cell     26 
2.3.5 Extraction of RNA from blood      26 
2.3.6 Extraction of RNA from tissue      26 
 IV
2.4 Detection of p53 codon 72 polymorphism     27 
2.4.1 Purification of PCR product      28 
2.4.2 Restriction digestion of PCR product (exon 2-4) to detect genotype 28 
2.4.3 Sequencing of PCR product      29 
2.5 One-step RT-PCR to amplify p53 gene     29 
2.5.1 Sequencing of one-step RT-PCR product      30 
2.6 Semi-quantitative one-step RT-PCR     31 
2.6.1 Semi-quantitative PCR       31 
2.6.2 Reaction condition for semi-quantitative PCR    33 
2.7 Analysis of cell death       33 
2.7.1 Analysis of cell cycle        34 
2.8 Luciferase reporter assay       35 
2.8.1 Luciferase assay        35 
2.8.2 β-gal assay         36 
2.8.3 Host-cell reactivation assay       36 
2.9 Western blotting        37 
2.10 Measuring melanin content       38 
2.11 Generating p53 mutants using SDM     38 
2.11.1 Primers for SDM        39 
2.11.2 Generating temperature sensitive p53     40 
2.12 Preparation of bacterial competent cell     40 
2.12.1 Bacterial transformation       41 
2.12.2 Large scale preparation of plasmid DNA     41 
 V
2.13 Unscheduled DNA synthesis      42 
2.14 South-Western analysis       42 
2.15 Micronucleus analysis       42 
2.16 Immunoprecipitation       43 
2.17 DNA and tissue samples       44 
 
CHAPTER 3: RESULTS 
3.1 Distribution and expression of p53 codon 72 polymorphic variants 45 
3.1.1 Distribution of p53 polymorphism in Singapore    45 
3.1.2 Expression of the p53 Codon 72 allele in Healthy Heterozygotes  47 
3.1.2.1 Expression of p53 allele in Chinese Healthy Heterozygotes  47 
3.1.2.2 Expression of p53 allele in European Healthy Heterozygotes  51 
3.1.2.3 Comparison of Expression of p53 allele in Chinese and    51 
            European Healthy Heterozygotes 
3.1.3 Expression of the p53 allele in breast cancer tissues   52 
3.1.3.1 p53Arg was higher in breast cancer tissues than healthy subjects 52 
3.1.3.2 Histologically normal tissues from Chinese breast cancer  53 
 patients preferentially express the p53Arg allele 
3.1.4 Mutational status of p53 in breast cancer     53 
3.2 Significance of p53 polymorphism, properties and function  59 
3.2.1 Role of p53 polymorphism in DNA repair     59 
3.2.2 Regulation of p53 dependent DNA-repair target gene promoters 60 
by p53Pro and p53Arg variants 
 VI
3.2.2.1 Expression of Gadd45 promoter in presence of either p53Pro  60 
 or p53Arg 
3.2.2.2 Expression of p53R2 promoter      61 
3.2.2.3 Expression of p53 target gene promoters as a control   62 
3.2.3 p53 inducible gene expression in isogenic cell lines expressing  67 
the p53Arg or p53Pro 
3.2.4 DNA repair assay using temperature sensitive-isogenic stable  67 
cell lines 
3.2.4.1 Apoptosis induce by temperature sensitive p53- isogenic cell lines 68 
3.2.4.2 p53 dependent DNA-repair genes are differentially regulated   68 
by p53Pro- and p53Argexpressing isogenic cell lines 
3.2.4.3 Gadd45 expression        71 
3.2.4.4 Induction of p48 by two p53 polymorphic variants   71 
3.2.4.5 Ribonucleotide reductase gene, p53R2     73 
3.2.5 Repair of exogenously damaged plasmids by p53 polymorphic forms 76 
3.2.5.1 Host-cell reactivation assay       76 
3.2.5.2 In vivo end-joining assay       81 
3.2.6 Unscheduled DNA-synthesis in p53Pro and p53Arg expressing cells 81 
3.2.7 Removal of cyclobutane pyrimidine dimers by p53 polymorphic  86 
forms 
3.2.8 Formation of micronucleic in p53Pro or p53Arg expressing cells 92 
3.3 p53 polymorphism and melanin synthesis     96 
 
 VII
3.3.1 Expression of TRP-1 and Tyrosinase promoters in two p53  97 
polymorphic  forms 
3.3.2 Synthesis of melanin in presence of two p53 polymorphic forms 99 
3.3.3 Synthesis of melanin in presence of endogenous p53   103 
polymorphic variants 
3.4 p53 mutations and response to chemotherapeutic drugs   108 
3.4.1 Generation of mutant p53 expressing isogenic cell line   108 
3.4.2 Effect of p53 mutation and polymorphic status in H1299 cells to 108 
anticancer drugs 
3.4.3 p53 polymorphism affects the response in H1299 cells expressing 109 
249-p53 to doxorubicin 
 
 
CHAPTER 4: DISCUSSION        
4.1 Distribution and expression of p53 codon 72 polymorphism  112 
4.1.1 Expression of p53 allele in healthy heterozygotes    113 
4.1.2 Expression of p53 allele in breast cancer patients    114 
4.1.3 Association of p53Arg allele in breast cancer susceptibility  115 
4.1.4 Mutation of p53 in breast cancer      116 
4.1.5 Wild-type p53Arg form may predispose to breast cancer  117 
4.1.6 Expression of p53 codon 72 allele can be used as a predictive  118 
factor in cancer development 
4.2 Functional significance of p53 polymorphism    119 
 VIII
4.2.1 p53 polymorphism and DNA repair     119 
4.2.2 p53Arg allele is less efficient to repair damaged DNA   121 
4.2.3 Weaker property of p53Arg in DNA repair may cause cellular   121 
 transformation 
4.2.4 Subtle difference between two polymorphs may affect p53’s  122 
downstream function significantly 
4.2.5 Role of p53 codon 72 polymorphism in preventing skin cancer  124 
4.3 Effect of p53 polymorphism in melanin synthesis    124 
4.3.1 p53Pro may protect individual from UV-induce stress   126 
4.3.2 p53Arg allele predispose to skin cancer     127 
4.3.3 p53 hotspot mutants along with two polymorphic forms   128 
  
CHAPTER 5: CONCLUSION       130 
REFERENCES         134 












Polymorphism at codon 72 residue of p53 results in either the p53Arg or p53Pro form 
of p53, whose functional significance in carcinogenesis is controversial. In this study 
we have investigated the population distribution, expression and functional significance 
of these two p53 polymorphic variants.   
 
Results show that Chinese population has predominantly p53Arg allele which is similar 
to Europeans, whereas p53Pro is relatively higher in the Indian population. p53Pro and 
p53Arg was found almost equally in Malay population. In this study population, a large 
number of individuals comprise heterozygote (p53Arg/p53Pro). Since the normal 
frequency of p53Pro allele is higher in this equatorial region, the expressing alleles in 
Chinese healthy heterozygotes have been investigated. Interestingly, it has been 
observed that Chinese healthy heterozygotes preferentially expressed the p53Pro allele. 
However, the expression of p53Pro allele in Chinese healthy heterozygotes 
(p53Arg/p53Pro) suggests that there is a selection preference on the expression of p53 
alleles. To understand this phenomenon, expression of p53 allele was observed in 
European (Polish) healthy heterozygotes (p53Arg/p53Pro). This population shows 
preferential expression of p53Arg allele which is opposite to that of Asian population. 
Thus, the distribution and expression of p53 codon 72 polymorphism may be selective 
and p53Pro is favoured in the equatorial region whereas p53Arg is favoured in the 
European population.  
 
 X
To understand the functional significance of this polymorphism and its distribution, we 
have analyzed p53 polymorphism in Chinese breast cancer population. There was no 
significant association of any particular p53 genotype in this breast cancer population; 
however, expression of p53Arg allele was significantly higher in heterozygote breast 
cancer patients. Furthermore, most of the p53Arg forms do not have any mutation 
whereas most of the p53Pro forms carry mutation in the DNA binding domain of p53. 
So, the data suggest that the expression of p53Arg allele may lead to cancer 
development in Asians. Thus, the expression status of the p53 polymorphs, rather than 
the genotypic status, might be a useful indicator for cancer susceptibility.  
 
Therefore, it can be predicted that p53 codon 72 polymorphism may affect p53’s 
function. To understand this phenomenon, we have analyzed whether the p53 codon 72 
polymorphism affects p53’s response to maintain genomic integrity. It has been found 
that p53Pro is more efficient than p53Arg in specifically activating several p53-
dependent DNA-repair target genes and p53Pro cells have a significantly higher DNA-
repair capacity than the p53Arg cells. Nucleotide excision repair induced by UV was 
significantly higher in p53Pro expressing cells. Defect in nucleotide excision repair 
after UV is one of the main causes of UV-induced skin cancer. This functional 
difference in DNA repair suggests that p53 genotype as well as their expression may 
increase cancer risk. 
 
p53 codon 72 polymorphism is associated with skin complexion; p53Pro is predominant 
in population with darker tan whereas p53Arg is higher in fair skinned population. So, it 
 XI
was predicted that p53Pro helps to produce more melanin in the population in equatorial 
region where this particular genotype (p53Pro) is predominant. As hypothesized, in 
vitro analysis showed that p53Pro form induces more melanin synthesis than p53Arg 
form. Melanin contents in several human cell lines with endogenous p53Pro or p53Arg 
also show the similar result. This interesting observation suggests that individuals with 
p53Pro form can survive better in regions where solar UV is a risk factor for skin cancer 
than p53Arg counterparts by producing more melanin. Thus, together with DNA repair 
capacity, it can be predicted that p53Pro individuals protect themselves by producing 
more melanin which absorbs UV and by removing cyclo pyrimidine dimers (CPDs) in 
the Equatorial region where p53Pro is significantly higher than European population. 
 
To further explore the properties of p53 codon 72 polymorphism, effect of mutations in 
p53 along with polymorphism have been investigated. Isogenic lung cancer cell lines 
with six p53 hotspot mutations in conjunction with the codon 72 polymorphism have 
been used for their response to a variety of anticancer drugs, either alone or in 
combination. The data show that the status of codon 72 polymorphism and p53 
mutations affects cellular sensitivity to cancer drugs and p53 codon 72 polymorphism 
can be used as a means for predicting treatment response. 
  
Thus, the expression p53 codon 72 polymorphism might be a determinant of cancer 
development and expression of p53Arg may enhance the individual’s probability to 
develop breast and skin cancer. Also the data on drug sensitivity by p53 mutants 
suggest that different p53 mutation along with codon 72 polymorphism modulate their 
 XII
response to chemotherapeutic drugs. The p53 codon 72 polymorphism is therefore 
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Chapter 1. Introduction 
Living cells are constantly exposed to several types of intrinsic and extrinsic genotoxic 
stress. These stresses may cause physical injury to the cell and the cells die because of 
the injury. However, if the damage is confined to the DNA level, it is necessary for the 
cell to repair or fix the damage or if cannot be repaired, the defective cell should be 
eliminated from the body. To execute these processes, cells may need to arrest cell 
cycle, to repair of the damaged DNA, or they may commit cellular suicide or apoptosis. 
Several genes are involved in these processes. The best understood one is p53 which 
acts as a cellular gate keeper by controlling those functions.  
 
1.1  p53, the tumour suppressor 
Linzer and Levine (1979) and Lane and Crawford (1979) first detected p53 in 
complexes with SV40 T antigen. Since then numerous research has been done on this 
gene. p53 gene is approximately 20 kb long with 11 exons and is located on short arm 
of chromosome 17, at 17p13.1. The gene product is a 393 amino acid (in human), which 
codes for a 53 kd nuclear phosphoprotein, hence the protein’s name. p53 was originally 
thought to be an oncoprotein since it is over expressed in tumors. So it was thought that 
this protein might be implicated in cellular transformation and tumourigenesis (Reich 
and Levine, 1984). Later it was observed that in most of the tumors, p53 is mutated 
(Baker et al., 1989) and it was subsequently demonstrated that wild type p53 acts as a 
potent suppressor of cellular transformation. It is now clear that wild type p53 is a 
tumor suppressor gene which prevents oncogenesis by inducing apoptosis of defected 
cells (Takahashi, 1989; Lane and Benchimol, 1990). The p53 tumor antigen is found in 
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increased amounts in a wide variety of transformed cells. The protein is also detectable 
in many actively proliferating, nontransformed cells, but it is undetectable or present at 
low levels in resting cells. 
 
1.1.1 p53 acts as a “Guardian of the Genome” 
p53 is a multifunctional sequence specific transcription factor. Upon stress p53 is 
activated and transactivates its downstream genes. It activates a number of genes which 
play a significant role in cellular physiology as well as maintaining genomic integrity. 
Activation of p53 can induce several responses in cells including apoptosis, cell cycle 
arrest, DNA repair, senescence, differentiation and inhibition of angiogenesis. But the 
best understood function of p53 is the ability to induce apoptosis (Bates and Vousden, 
1999), cell cycle arrest (El-Diery et al., 1993) and DNA repair (Kastan et al., 1992). 
Because of these properties, p53 gene is considered as a “guardian of the genome”. 
 
p53 protein lies at the heart of  stress response pathways that prevent the growth and 
survival of potentially malignant cells. Stress signals like DNA damage induces 
expression of p53, which in turn arrests the cell cycle, presumably to allow DNA repair 
(Lane, 1992) or drives cells to apoptosis if the damage is too extensive (Liebermann et 
al., 1995). By this way p53 prevents proliferation of cells with damaged DNA and 





1.1.2 p53 and DNA damage response pathways:  
p53 is a transcriptional regulator and has pleiotropic functions including cell cycle 
control, DNA repair, apoptosis and genomic integrity. Upon DNA damage, p53 is 
activated and the regulation of p53 is controlled both transcriptionally and through 
posttranslational modifications including phosphorylation and acetylation (Sakaguchi et 
al., 1998; Meek, 1998). The p53 protein is phosphorylated on a number of sites 
following DNA damage including Serine residues 6, 9, 15, 20, 33, 37 and 392, and 
acetylated on Lysine residues 320, 373 and 382 (Sakaguchi et al., 1998; Ko et al., 1997; 
Chehab et al., 1999; Shieh et al., 1997; Lu et al., 1998; Knippschild et al., 1997; 
Kapoor and Lozano, 1998; Blaydes and Hupp, 1998; Siliciano et al., 1997). Once 
activated, p53 forms a tetramer and binds to the p53 responsive element on the target 
genes and stimulates their transcription. 
 
1.1.3 DNA repair and p53 
Since cells are constantly exposed to both endogenous and exogenous genotoxic agents 
that damage DNA and threaten their genomic stability (Lindahl, 1993), DNA repair is 
an important molecular defense system against agents that cause cancer, degenerative 
diseases, and aging. Several repair systems in human protect the genome by repairing 
modified bases, DNA adducts, crosslinks, and double strand breaks. These repair 
systems, base excision, nucleotide excision, and recombination, are intimately 
connected to transcription and cell cycle checkpoints. Genotoxic stress induces a set of 
cellular reactions mediated by p53.  p53 is activated upon stress and active p53 induces 
apoptosis, DNA repair or cell cycle arrest. p53 performs this function by the regulation 
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of several cellular processes and it serves as a sequence-specific transcriptional 
activator of genes that contain p53 responsive elements. Since p53 is involved in the 
regulation of these distinct processes, the protein should be able to respond quickly to 
changes of the cell surroundings. Abrogation of its function therefore leads to a more 
aggressive cancer.  
 
Mutations in p53 or in the pathway that directly it regulates have been found in over 
80% of human tumors. One of p53’s functions in the damage response is the activation 
of genes that initiates apoptosis. p53 has also been shown to arrest the cell cycle in 
response to DNA damage, thus preventing the replication of damaged DNA. These 
functions are mainly governed by p53’s down stream-effector genes, such as p21, 
Mdm2, Gadd45, Bax, etc. 
 
The G1/S checkpoint prevents cells from entering the S phase in the presence of DNA 
damage by inhibiting the initiation of replication. Under suitable conditions, cells in the 
G1 phase of the cell cycle become committed to enter the S phase at a stage called the 
restriction point in mammalian cells and start in budding yeast (Pardee, 2002). The 
restriction point precedes the actual start of DNA synthesis by about 2 hours in human 
cells. If there is DNA damage, however, entry into S phase is prevented regardless of 
whether the cells have passed the restriction point. Current evidence suggests that if the 
DNA damage is double-strand breaks caused by ionizing radiation or radiomimetic 
agents, ATM is activated and phosphorylates many target molecules, notably p53 and 
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Chk2. These phosphorylations result in the activation of two signal transduction 
pathways, one to initiate and one to maintain the G1/S arrest (Bartek and Lukas, 2001). 
 
1.1.4 Cell cycle arrest by p53 
After DNA damage, many cells appear to enter a sustained arrest in the G1 and G2 
phase of the cell cycle. The p53-regulated cyclin-dependent kinase inhibitor p21 is a 
primary mediator of the p53-depedent G1 arrest following DNA damage (Harper et al., 
1993). It is believed that p53 activation signals the G1 arrest to delay the transit from 
G1 to S, thus preventing the effects of DNA lesions on vital cellular functions. If the 
DNA damage is by UV light or UV-mimetic agents, the signal is sensed by ATR, 
Rad17-RFC, and the 9-1-1 complex, leading to phosphorylation of Chk1 by ATR. The 
activated Chk1 then phosphorylates Cdc25A, leading to G1 arrest. This rapid response 
is followed by the p53- mediated maintenance of G1/S arrest, which becomes fully 
operational several hours after the detection of DNA damage (Bartek and Lukas, 2001). 
In the maintenance stage, ATM or ATR phosphorylates Ser15 of p53 directly and Ser20 
through activation of Chk2 or Chk1, respectively (Banin et al., 1998; Canman et al., 
1998; Kastan and Lim, 2000; Ryan et al., 2001; Chebab et al., 1999). The 
phosphorylation of p53 inhibits its nuclear export and degradation, thus resulting in 
increased levels of p53 (Zhang and Xiong, 2001). p21WAF-1/Cip1, activated by p53, 
binds to and inhibits the S-phase-promoting Cdk2-CyclinE complex, thereby 
maintaining the G1/S arrest. p21WAF-1/Cip1 also binds to the Cdk4-CyclinD complex 
and prevents it from phosphorylating Rb (Harper et al., 1993). The phosphorylation of 
Rb results in its release of the E2F transcription factor, which is required for the 
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transcription of S-phase genes in order for S phase to proceed (Bartek et al., 2001; Lin 
et al., 2001). 
 
At high doses of UV, by contrast, p53 does accumulate during G1 even in excision 
repair-defective cells. Indeed, a recent report shows that in budding yeast, activation of 
the G1/S checkpoint at moderately high UV doses is independent of excision repair 
(Zhang et al., 2003). It is possible that cyclobutane pyrimidine dimers, which 
predominate at low doses of UV, do not constitute a significant signal for checkpoint 
activation, but that (6-4) photoproducts, which become a substantial fraction of the 
damage at high UV doses, can be recognized by the damage sensors for checkpoint 
activation. 
 
Recent findings on p53 polymorphism and cell cycle progression suggest that these two 
forms of p53 may regulate cell cycle regulating genes in different manner (Pim and 
Banks, 2004). The p53 form which induces cell cycle arrest genes at a lesser extent after 
DNA damage may allow accumulation of mutations in DNA and contribute to overall 
genomic instability and cancer susceptibility.  
 
1.1.5 Role of p53 in DNA repair 
The most versatile cellular pathway for dealing with a large variety of structurally-
unrelated DNA alteration is nucleotide excision repair (NER). There are two 
subpathways of NER, termed global genomic repair (GGR) and transcription coupled 
repair (TCR). GGR deals with all repairable lesions throughout the genome, while TCR 
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is selective for the transcribed DNA strand in expressed genes (Hanawalt et al, 2003). 
Nucleotide excision repair (NER) is an essential DNA repair pathway for reversing 
DNA damage caused by ultraviolet light or other DNA cross-linking agents. NER can 
function in two ways. The first is transcription-coupled repair (TCR), whereby DNA 
lesions are repaired on the transcribed strand of active genes. The second is global 
genome repair (GGR), whereby DNA lesions are recovered genome-wide (Friedberg et 
al., 1995; Hanawalt, 1992). TCR is associated with RNA polymerase II activity and 
targets DNA lesions where RNA polymerase II is stalled (Hanawalt, 1992; Sweder and 
Hanawalt, 1992; Selby and Sancar, 1993). GGR involves scanning along the genome by 
specific damage recognition proteins in search of DNA lesions (Friedberg et al., 1995). 
Once DNA lesions are encountered, the recognition proteins recruit other NER factors 
and initiate the NER process.  
 
1.1.5.1 Gadd45 activation by p53 
The growth arrest and DNA-damage inducible 45 gene (Gadd45) is one of the 
downstream target of p53 (Fornace, 1992). Gadd45 can induce G1 arrest (Smith et al., 
1994; Zhan et al., 1994) and stimulates DNA excision repair (Smith et al., 1994).  
Gadd45 is a p53-regulated factor and contributes significantly to DNA repair (Carrier et 
al., 1994; Smith et al., 2000; Smith et al., 1996). Gadd45 is able to bind to UV-
damaged chromatin, perhaps facilitating access to regions of DNA damage (Smith et 
al., 1996). As a sensitive response factor, the gadd45 is rapidly induced to promote 
GGR efficiency for DNA damage of the genome (Hsien-Chang et al., 2003). 
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Since Gadd45 is an NER enhancer, its expression should provide information on the 
DNA repair efficiency of a given cell line. GADD45 promotes G2/M arrest via nuclear 
export and kinase activity of Cdc2, increases global genomic DNA repair, and inhibits 
cell death in keratinocytes (Maeda et al., 2002). Among the p53 effector genes, Gadd45 
shows a strong and specific induction after UV B irradiation. Thus GADD45 plays an 
important role in maintaining genomic integrity in ultraviolet-exposed skin. 
 
1.1.5.2 p53R2 activation 
Ribonucleotide reductase plays a key role in the synthesis of DNA and is responsible 
for the reduction of ribonucleotides to their corresponding deoxiribonucleotides, 
providing a balanced supply of precursors for DNA synthesis and repair (Wright et al., 
1990; Hurta and Wright, 1992). 
Tanaka et al. (2000) identified a novel ribonucleotide reductase gene, p53R2, a putative 
tumor suppressor, which encodes a protein with striking similarity to a small subunit of 
ribonucleotide reductase. They found that DNA synthesis in cells arrested in G1 or G2 
after DNA damage was mediated through the ribonucleotide reductase activity of 
p53R2 and it (p53R2) might be directly involved in processes designed to repair the 
damage. Later it was shown that p53R2 is directly induced by wild type p53 and 
involved in the p53 checkpoint for repair of damaged DNA. (Byun et al., 2002).  p53R2 
contains a p53-binding sequence in intron 1 and  wild type p53 directly interacts with 
p53R2. In response to UV irradiation, p53R2 dissociates from p53 and translocates to 
the nucleus to form an active ribonucleotide reductase complex to provide dNDPs for 
DNA repair (Xue et al., 2003; Tanaka et al., 2000). 
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The expression of p53R2 can be induced by wild type p53 in response to various 
genotoxic stresses, including γ-irradiation, UV-irradiation, or exposure to adriamycin 
(Yamaguchi et al., 2001).  p53 appears to participate directly in DNA repair by 
inducing p53R2 in response to DNA damage. Thus, inactivation of p53 could directly 
interfere with damage-induced transcription of p53R2, enhance mis-incorporation of 
dNTPs, and increase the frequency of mutations, resulting in genomic instability in 
cancers where p53 has undergone mutation (Yamaguchi et al., 2001). Yamaguchi et al 
(2001) showed that inactivation of either p53 or its transcriptional target, p53R2, should 
interfere with regulation of the p53-dependent DNA repair pathway and increase the 
sensitivity of cells to anticancer drugs. They found that a point mutation of p53R2 in 
cancer cell line HCT116 resulted in loss of ribonucleotide reductase activity. In those 
cells, DNA damage-inducible apoptotic cell death was enhanced through transcriptional 
activation of p53AIP1. Expression of p53AIP1 is a pivotal mediator for p53-dependent 
apoptosis. Severe DNA damage or inactivation of the p53R2 might induce p53AIP1 
expression which causes activation of p53-dependent apoptotic pathway to eliminate 
unrepaired or defected cells by apoptosis (Yamaguchi et al., 2001). 
 
1.2 Functions of different domains of p53 
p53 is a sequence-specific transcriptional activator and several functional domains have 
been identified within the protein. The main phosphorylation domains are the N and the 
C terminus. The N-terminal part (aa1 to aa91) contains the transcription-regulatory 
domain of p53, while the C-terminal domain (aa300 to aa393) controls the specific 
DNA binding by p53 (Steegenga et al., 1996). The C-terminal domain of p53 may 
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compete with the p53 transactivation domain for a common basal transcription factor 
(Shaulian et al., 1995) and a full apoptotic response to p53 requires both its amino and 
carboxyl terminus (Chen et al., 1996; Zhu et al., 2000).  
 
The N-terminus of p53 contains a bi-partite transactivation region (aa20-aa60) and a 
region containing several copies of the motif PXXP, the proline rich domain (aa60-
aa91) which is involved in mediating apoptosis (Walker and Levine, 1996; Sakamuro et 
al., 1997; Venot et al., 1998).  Mutation at residues aa53-aa54 (in the activation 
domain) abrogates the apoptotic activity but has no significant effect on cell cycle arrest 
and p53 which lacks both proline rich domain and C-terminal basic domain, is defective 
in inducing apoptosis but is capable of inducing cell cycle arrest (Zhu et al., 2000). 
Because of these different properties of different domains, it is important to detect their 
alterations in tumors to select the suitable therapeutic strategy. 
 
On the other hand, the C-terminal basic domain has been subjected to extensive 
analysis, and evidences suggest that the basic domain is a regulatory domain (aa363- 
aa393). This regulatory domain may have a role in DNA damage recognition (Lee et 
al., 1995; Reed et al., 1995) and it can regulate the DNA binding activity when it is 
phosphorylated, acetylated, deleted, or associated with anti-p53 antibody. 
 
Thus, the C-terminal basic domain is a negative regulatory domain whose effect on the 
DNA binding activity can be alleviated by interacting with other cellular proteins, 
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peptides derived from the p53 C-terminus, or other modifications. The types of 
mutations in these domains in two p53 polymorphs are not well studied. 
 
1.3 Drug and Chemotherapy Resistance by mutant p53
Aas et al. (1996) presented data linking specific mutations in the p53 gene to primary 
resistance to doxorubicin therapy and early relapse in breast cancer patients. The L2 
domain (codons 163-195) and the L3 domain (codons 236-256) contain zinc finger 
sequences and are involved with p53's DNA binding function. p53 mutations in patients 
with progressive disease all affected the L3 domain. Some patients with L3 mutations 
expressed primary resistance to anthracycline therapy. Patients with p53 mutations 
affecting the zinc binding domain who responded to primary chemotherapy initially in 
most cases had a relapse of their disease within 3 months. Two hotspots of the p53 gene 
are in this zinc finger sequences, those are codon 248 and codon 249. Other four 
hotspots are also frequent in human cancer which might have different type of response 
to drugs.  
 
Because response to chemotherapeutic drugs depends on the type of mutation in p53 
and a specific drug may not be effective to all types of tumor with different p53 
mutations, we hypothesize that drugs that target p53 may have varying effect on 





1.4 p53 polymorphism 
There are 33 single nucleotide polymorphism (SNP) found in entire human p53 gene, 
only six of the SNPs are present in the exons (exons 2, 4 and 6). Among these six SNPs, 
only two SNPs at codon 47 and codon 72 residues in exon 4 alter amino acid sequences; 
codon 47: proline – serine and codon 72: arginine – proline ( IARC Database). p53 
variant with a serine at codon 47 is considered as a rare germ-line polymorphism that 
does not alter the growth-suppression activity of p53 (Felley-Bosco et al., 1993). The 
most common polymorphism of p53 is found at codon 72. A single nucleotide 
polymorphism (SNP) at 209 base pair in exon 4 of p53 gene causes this amino acid 
substitution where “ccc” codes for a Proline and “cgc” codes for an arginine. Both 
forms are morphologically wild type and can be detected by wt- p53 specific 
monoclonal antibody and they have similarity in binding to DNA in a sequence specific 
manner (Harris et al., 1986; Thomas et al., 1999).  
 
Differences among p53 polymorphs have been reported for several types of cellular 
events. The two polymorphs differ in their ability to induce apoptosis (Drumont et al., 
2003), E6-mediated p53 degradation (Kawaguchi et al., 2000) and cell cycle 
progression (Pim and Banks, 2004).  Based on the migration pattern in SDS-PAGE, 
Thomas et al. (1999) proposed conformational differences of these two wild type forms. 
The first important findings regarding this p53 polymorphism was done by Storey et al. 
(1998). Storey et al. (1998) reported a 7-fold increased risk of cervical cancer 
associated with having an Arg/Arg polymorphism at codon 72 of p53 compared with 
the Pro/Arg heterozygotes.  
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1.4.1 Distribution of p53 codon 72 polymorphism 
Beckman et al. (1994) reported for the first time that the distribution of p53 
polymorphism is associated with both geographical and ethnic origin. Subsequently 
several studies have been done on different types of human malignancy and its 
association with p53 polymorphs all over the world. In Asia, studies have been done in 
China (Shen et al., 2004; Peixoto et al., 2001), Hong Kong (Ngan et al., 1999), India 
(Katiyar et al., 2003), Iran (Pezeshki et al., 2001), Israel (Arbel-Alon et al., 2002), 
Japan (Huang et al., 2003; Murata et al., 1996), Korea (Baek et al., 2000), Taiwan 
(Yang et al., 2001) and Thailand (Tiwawech et al., 2003). However, no clear 
association was made between this polymorphism and the occurrence of the different 
type of cancers or any other p53 related diseases in the Singaporean population. In this 
study, distribution of this p53 polymorphism (codon 72) in healthy as well as breast 
tumor population in Singapore has been studied along with the biological significance 
of these two p53 polymorphic forms in cancer treatment and therapy. 
 
1.4.2  p53 polymorphism in human malignant diseases 
1.4.2.1 Breast cancer 
In Japan, p53Pro was found significantly higher than p53Arg or p53Pro/Arg in breast 
cancer (Huang et al., 2003) and prostrate cancer (Suzuki et al., 2003) population. But in 
Turkish breast cancer population, a significantly higher prevalence of p53Arg/Arg 




1.4.2.2 Skin cancer 
p53 polymorphism has been implicated in skin cancer. High proportion of p53Arg allele 
has been found in skin cancer in several populations (de Oliveira et al., 2004; Chen et 
al., 2003). In Celtic population, study showed that about 80% of skin cancer patient 
carry p53Arg allele (O’Conner et al., 2001). 
 
1.4.2.3 Cervical cancer 
p53Arg/Arg genotype was found to be higher in cervical cancer in South Africa 
(Pegoraro et al., 2002), Israel (Arbel-Alon et al., 2002) and in HPV-associated cervical 
cancer in Indian women (Nagpal et al., 2002). Several factors can influence the risk of 
cervical cancer, such as: HPV infection (Rydstrom and Tornberg, 2006; Dahlgren et al., 
2006), lifestyle (Rieck and Fiander, 2006) and sexual behaviour ( Matos et al., 2005); 
however, those observations suggest an association with p53Arg form and cervical 
cancer.  
 
1.4.2.4  Gastric cancer 
Shen et al. (2004) found that p53Arg allele is significantly associated with increased 
risk of gastric cancer. Hiyama et al. (2002) suggested that p53 codon 72 polymorphism 
may serve as a genetic marker for the risk assessment of the diffuse-type gastric cancer 
development in patients with Helicobacter pylori-associated chronic gastritis. They 
found that p53Pro/Pro genotype was associated with a 2.98 fold higher risk in this type 
of cancer compared with p53Arg/Arg.  
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1.4.2.5 Other cancers 
p53Pro form appeared to be a significant risk factor for the development of primary 
open angle glaucoma (Lin et al., 2002). Li et al. (2002) suggested that p53Arg/Arg 
genotype is one of the high risk genetic factors in HPV-associated malignancies among 
the Chinese population. Papadakis et al. (2002) reported p53Arg homozygosity is 
associated with advanced lung cancer. Individuals with p53Pro form are at higher risk 
to develop nasopharyngeal cancinoma (Tiwawech et al., 2003; Tsai et al., 2002). 
Soulitzis et al. (2002) reported that p53Arg/Arg genotype has an increased risk of 
developing bladder cancer. In urinary tract carcinoma p53Arg allele has been found 
preferentially mutated and this number increases with the increase in tumor stage 
(Furihata et al., 2002). Similar finding were observed in nonmelanoma skin cancer 
where mutations are mostly (93%) in the p53Arg allele (McGregor et al., 2002). 
However, in non-small cell lung cancer the p53 Pro allele is associated with an 
increased frequency of p53 mutations (Hu et al., 2005). 
 
But the actual role of the p53 polymorphism in carcinogenesis is not well-investigated. 
It is still controversial and unclear which form of p53 is more prone to cancer. 
Accumulated information suggests that these two p53 polymorphic variants may have 






1.5 Functional difference of p53 polymorphs   
p53 codon 72 polymorphism is located in the proline-rich region at the N-terminal of 
p53 protein. This proline-rich region plays a role in p53-mediated apoptosis and growth 
suppression (Walker and Levine, 1996; Sakamuro et al., 1997; Venot et al., 1998). 
Therefore, it can be predicted that a substitution of one amino acid in this region may 
lead to functional differences between these two p53 polymorphs.   It is now well 
established that these two polymorphs are naturally selected and they may have a role in 
ecological adaptation (Beckman et al., 1994; Sjalander et al., 1996). The significance of 
these two wild type forms in molecular level of carcinogenesis is not well studied 
though there are some reports on the association of a specific p53 with certain types of 
cancer. The present study was aimed to understand the association of p53 
polymorphism in breast cancer in relation with the differences of mutational trend 
which can explain some of the differential properties of the p53 polymorphism in 
carcinogenesis.  
 
1.5.1 Implication of p53 polymorphism to drug sensitivity along with mutation  
In some cancers, the presence of specific type of p53 mutation may be predictive of the 
tumor response to treatment and patient survival. Since p53 polymorphism may have 
differential effect on apoptosis and inducing cell cycle arrest, drugs that target p53 may 
have varying effect on individuals with different p53 genotypes. 
 
Head and neck cancer cells expressing the wild-type p53Arg variant were shown to be 
more sensitive to a variety of anticancer drugs and head and neck cancer patients had a 
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longer survival compared with their p53Pro-expressing counterparts (Sullivan et al., 
2004), indicating that the status of the p53 codon 72 polymorphism could influence the 
outcome of cancer therapy. Biochemical analysis has shown that 72R mutants were 
capable of binding to p73, the structural and functional homologue of p53, and 
inactivating it (Marin et al., 2000). This property of mutant p53 to bind and neutralize 
p73-mediated apoptosis was enhanced when the p53 was in the p53Arg form compared 
with the p53Pro form, especially when tested using the human SAOS-2 osteosarcoma 
cells (Marin et al., 2000). In addition, this negative inhibitory effect was shown to be 
specific for mutant forms of p53, because wild-type p53 was shown not able to bind p73 
(Strano et al., 2000; Di Como et al., 1999). Accordingly, clinical response following 
cisplatin based chemotherapy for advanced head and neck cancer was shown to be 
influenced by this polymorphism, as cancers expressing p53Arg mutants were found to 
have lower response rates than those expressing the p53Pro mutants (Bergamaschi et 
al., 2003). Thus, polymorphism at codon 72 of p53 can have opposing effects on 
response to therapy according to the status of p53 (Bergamaschi et al., 2003; Sullivan et 
al., 2004). 
 
Recently Sullivan et al. (2004) reported that p53 codon 72 polymorphism might affect 
p53’s response to chemotherapy both in vitro and in vivo. This suggests that p53 codon 
72 polymorphism is an important determinant of response to anticancer agents in cells 
or individuals expressing wild type p53. Intact p73 function is shown to be an important 
determinant of cellular sensitivity to anti cancer agents (Bergamaschi et al., 2003). 
Inhibition of p73 function by mutant p53 abrogates apoptosis and cytotoxicity induced 
by these agents. p53 codon 72 polymorphism influences inhibition of p73 by a range of 
 17
p53 mutants in squamous cancers. This polymorphism influences cisplatin-based 
chemotherapy in head and neck cancers where cancers with p53Arg mutants have lower 
response rate than the cancers with p53Pro mutants (Bergamaschi et al., 2003). 
 
Until now, it is not clear if the expression of mutant 72p53Arg forms would contribute 
to chemotherapeutic resistance and poor prognosis in all cancer types. We have now 
done a systematic analysis using the p53 null H1299 human lung cancer cell line, to 
evaluate the sensitivity of isogenic cell lines expressing the six common hotspot p53 
mutations (i.e., R175H, G245S, R248W, R249S, R273H, and R282W), in conjunction 
with the codon p72 polymorphism, to several anticancer drugs. These cells have been 
evaluated for their response to individual drugs and to combination of drugs to mimic 
the clinical therapeutic regimens. Our results indicate that the expression of mutant 72R 
forms do not always confer resistance to anticancer drugs, suggesting that there may be 
cell type and mutation specific factors that influence the outcome of drug response.  
 
1.5.2 p53 polymorphism and breast tumor  
In breast cancer, inactivation of p53 is generally found in more advanced disease, with 
rates of inactivation up to 40% for non-invasive breast cancers and between 20 and 50% 
for invasive breast cancers (Allred et al., 1997; Davidoff et al., 1991). The information 
on p53 polymorphism and breast cancer is very limited. The point at which p53 
mutations most often arise in breast cancer progression remains an unresolved question 
(Elledge and Allred, 1998) and an important question is whether p53 is a predictive 
factor in breast cancer. 
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Loss of heterozygosity (LOH) of p53 allele has been reported. Papdakis et al (2002) 
reported LOH in p53 allele in lung cancer where they found that p53Pro allele is 
eliminated and p53Arg allele retained. In hepatitis C virus-associated carcinogenesis 
frequent loss of p53Pro allele has been observed (Anzola et al., 2003). In skin cancer 
frequent loss of p53Pro allele has been found in p53Pro/Arg tumors (McGregor et al., 
2002).  
 
In Singapore, breast cancer is one of the major malignant diseases in women. The status 
of p53 has been investigated. My observation showed that there is an association of p53 
polymorphism and breast tumour in our local population.  
 
1.5.3 p53 and melanin synthesis 
It has been reported that p53 can activate melanin synthesis genes (Nylander et al., 
2000; Kichina et al., 1996), thus, besides maintaining genomic integrity p53 also play a 
significant protective role against UV. 
Exposure to sunlight causes tanning of the skin. Sunlight contains UVB which induces 
pigment production in human skin (Friedmann and Gilchrest, 1987). This is a major 
photoprotective response of human skin. Epidermal melanin pigment is believed to 
prevent development of UV-induced skin cancer by shielding cell nuclei and reducing 
DNA damage formation. Melanin is a brown-black polymer (Noda et al., 1993) that can 
absorb UV photons and UV-induced free radicals before they can interact with cellular 
constituents (McGregor and Hawk, 1999). Kobayashi et al. (1993) showed that melanin 
reduces UV-induced DNA damage formation in cultured human melanoma cells. 
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Tyrosinase is a key enzyme in melanin synthesis and the expression of this gene is 
regulated by various hormones, carcinogens and environmental factors. It is induced 
after UV irradiation in which epidermal melanin content gradually increases over 
several days after exposure to the sun light. Khlgatian et al. (2002) showed that 
transcriptionally active p53 upregulates tyrosinase gene expression which subsequently 
increases melanin content. 
 
Several studies showed that distribution of p53 polymorphism has an association with 
skin complexion and geographic latitude. The frequency of p53Pro is higher in 
population with dark complexion near the equator, while the frequency of p53Arg is 
higher towards the north of the hemisphere. The distribution of p53 polymorphs shows 
a correlation between p53 polymorphism and latitude and this shows distinct 
differences between major ethnic groups (Beckman et al., 1994; Sjalander et al., 1996). 
In the equatorial region, which has the most exposure to sunlight and solar UV 
radiation, p53Pro is predominant, while in population with fair skin in Northern 
Hemisphere, p53Arg is predominant. 
 
Cultured melanocyte from fair-skinned individuals synthesized less melanin and 
produced more cyclobutane pyrimidine dimers and 6-4 photoproducts upon UVB 
exposure than did melanocyte from black skin (Smit et al., 2001). White Australians 
now have the highest rate of all kinds of skin cancer of any people in the world. The 
Australian experience has recognized that intense sun exposure and fair skin are 
important risk factors for skin cancer, with the dark complexion of indigenous 
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Aboriginal Australians sustaining little of these sun induced cancers (Leffel and Brash, 
1996).  
 
The above information tells that melanin synthesis mechanism works differently in 
different population and this mechanism may be controlled partially by p53 
polymorphic forms. In the present study, the role of p53 polymorphic variants in 
producing melanin has been investigated. 
 
The major carcinogenic agent for most skin cancers is solar/natural UV light. It is well 
established that DNA of the skin is the central target of UVB. When skin is exposed to 
sunlight, solar UV light is absorbed in DNA with the formation of UV-specific 
dipyrimidine photoproducts, mainly cyclobutane pyrimidine dimers or CPD (Ravanat et 
al., 2001) which, if not correctly repaired, can lead to the generation of deleterious 
mutations. Chronic exposure to sunlight may induce skin damage in the form of 
photoaging and photocarcinogenesis. Repeated exposure to low doses of UVB causes 
significant functional and molecular damage to keratinocytes, which might eventually 
predispose to skin cancer (Chouinard et al., 2001). To protect the skin, epidermal cells 
produce melanin and repair the CPD by nucleotide excision repair (Yarosh et al., 1991). 
CPD is thought to be involved in sunlight-induced melanogenesis. (Gloster and 
Broadland, 1996). Skin cancer is the most common malignancy in the people of 
European origin (population with white complexion) who have predominantly p53Arg 
allele. This indicates that p53Pro or p53Arg form may have differential property at 
removing these photoproducts (CPD).  A significant association has been observed in 
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between p53Arg/Arg genotype and susceptibility to sunburn and also p53Arg/Arg 
genotype was found significantly associated with non-melanoma skin cancer 
(McGregor et al., 2002).  
 
The investigation of the genetic differences between individuals who can and can not 
tan after exposure to sunlight may be important in differentiating the risk factors for 
predisposition to skin cancer. Based on these observations of p53 polymorphs 
involvement in melanin synthesis and apoptosis, we speculate that they may play a 
differential role in DNA repair via NER.  
 
The mechanisms underlying ultraviolet-induced melanogenesis offer the opportunity for 
novel therapeutic approaches aimed at minimizing acute and chronic photodamage in 
human skin.  
 
1.5.4 Nucleotide excision repair (NER) by p53 
To further explore the role of p53 polymorphism in protecting the human genome, a 
possible direct effect of p53 polymorphs on the removal of potentially mutagenic 
lesions upon DNA damage by nucleotide excision repair (NER) has been studied.  
 
UV-B triggers a cascade of events involving cell cycle control genes leading ultimately 
to DNA repair or apoptosis. The highly conserved vertebrate gene p53 plays a central 
role in the DNA damage response initiated by UV via several mechanisms. One of the 
important mechanisms is that p53 recognises and binds to certain types of DNA lesions 
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directly and stimulates DNA repair (Huang et al., 1998; Nelson et al., 1994). UV-
specific dipyrimidine photoproducts can be repaired by nucleotide excision repair 
(NER) or replicated by low fidelity class Y polymerases and activation of p53 is 
required for efficient repair of UV-induced CPDs in human fibroblasts (Ford and 
Hanawalt, 1997). 
 
Thus, detection and quantification of CPD is an important marker in the study of DNA 
damage induction and repair. Loss or abrogation of p53’s function leads to decreased 
rate of global genomic repair (GGR) after UV irradiation and affects CPD removal 
(Ford and Hanawalt, 1995; Ford and Hanawalt, 1997; Zhu et al., 2000).  
 
1.5.5 p53’s role in ecological adaptation 
Induction of apoptosis of keratinocytes by ultraviolet (UV) radiation is a protective 
phenomenon relevant in limiting the survival of cell with irreparable DNA damage. 
Changes in UV-induced apoptosis may therefore have significant impact on 
photocarcinogenesis. 
 
Alterations in UVB-induced DNA repair may have a profound impact in the induction 
of skin cancer, the most common malignancy in people of Western European origin, 
both in the United States and Europe (Gloster and Brodland, 1996). Also, it is well 
established that population with fair skin has the highest rate of skin cancer. It is 
believed that due to less melanin in their skin, solar UV can act on DNA on the 
epidermis more easily than the individual with high level of melanin in the skin. 
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Chapter 2. Materials and Methods 
2.1 Tissue culture 
p53 null human cell lines ; H1299 derived from lung cancer (ATCC), Saos-2 derived 
from osteosarcoma (ATCC ) and UISO derived from melanoma ( kindly provided by 
Prof  T Dasgupta, University of Illinois, USA) were used for in vitro assays.  
All cell lines were cultured in Dullbecoo’s modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Calf Serum (Hyclone) in water jacket incubator in 
presence of 5% CO2 at 370C. 
 
2.2 Transfection 
Cells were transfected by the lipofection method. Transfection reagents used were 
Lipofectamine and Plus Reagent purchased from Invitrogen (Invitrogen Life 
Technologies, USA). Cells were trypsinized and splitted into 10 cm tissue culture dish 
24 hours before transfection in order to have cells approximately 70% confluent at the 
time of transfection. The culture medium was replaced with serum free medium. DNA 
was mixed with Plus reagent and kept at RT for 15 minutes and then Lipofectamine 
added and incubated at RT for another 15 minutes which was then added to the culture. 
After 3 hours of incubation, normal serum containing medium was added and cells let 
to grow. After 14 to 16 hours of transfection, Llipofectamine containing culture medium 
was removed, the cells were washed with PBS and grown in normal serum containing 
medium. 72 hours following transfection, the transfected cells were selected using G418 
(Geneticin) or puromycin depending on the type of selection marker in the expression 
vector.   
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2.3 Extraction of DNA and RNA 
2.3.1 Extraction of genomic DNA from blood 
Genomic DNA was extracted from blood using commercially available blood DNA 
extraction kit (QIAampR DNA Blood Midi Kit, QIAGEN, Germany) according to the 
manufacturer’s protocol. 2ml of blood were mixed with 2.4ml AL Buffer (lysis buffer) 
and 200 µl proteinase K (provided). The mixture vortex briefly and incubated at 700C 
for 10 minutes. After adding 2 ml of absolute ethanol, the mixture was passed through 
cartridge provided and washed once with washing buffer AW1 and AW2. Finally, the 
genomic DNA bound onto the membrane was eluted using either elution buffer EB or 
distilled water.  
 
2.3.2  Extraction of genomic DNA from tissue:   
DNA was extracted using Promega SV Genomic DNA extraction kit. Tumor tissue as 
well as normal tissue were homogenized using electronic homogenizer and lysed with 
SV Lysis buffer, which is subsequently passed through the membrane cartridge and 
washed 4 times with SV wash buffer. DNA bound in the cartridge was eluted using 
distilled water and used for experiment.   
 
2.3.3  Extraction of genomic DNA from cultured cell 
Lysis buffer from Promega SV Genomic DNA extraction kit was added directly to the 




2.3.4 Extraction of RNA from Cultured cell 
Cells were washed with sterile 1XPBS and Trizol Reagent (Invitrogen) was added 
directly to the tissue culture plate, swirl gently to lyse the cell and transferred to 
centrifuge tube. 0.2ml chloroform/1ml Trizol was added and the mixture was shaked 
vigorously for 15 seconds and centrifuged for 15 minutes at 40C at 10,000g. The 
supernatant was transferred to a fresh tube and RNA was precipitated at room 
temperature for 10 minutes by adding 0.5ml isopropanol / 1ml Trizol. This was 
centrifuged at 10,000g at 40C for 10 min and RNA pellets were washed once with 75% 
ethanol. The RNA pellet was then resuspended in DEPC treated dH2O. Total RNA have 
been stored at –800C for all times. 
 
2.3.5 Extraction of RNA from blood 
Total RNA from blood samples were spin down to remove the serum and the pellets 
were incubated on ice with RBC lysis buffer containing 4M ammonium acetate. This 
has been repeated five times to remove all the RBC and the pellets containing 
leucocytes were used for total RNA extraction using Trizol as described above.  
 
2.3.6 Extraction of RNA from tissue 
Promega SV RNA extraction kit (USA) has been used to extract RNA from tissue 
samples. Tissue samples were homogenized in electronic homogenizer in presence of 
SV lysis buffer. 350ul of SV RNA lysis buffer was added to the tube and the tissues 
(~20gm) were homogenised until no visible tissue fragments could be seen. Then 700μl 
of SV RNA dilution buffer was added to the lysate, mixed and incubated at 70°C for 
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3mins. Samples were centrifuged at maximum speed (10,000g) for 10mins to remove 
cell debris and the clear lysate was transferred into a fresh tube without disturbing the 
pellet. 400μl of 95% ethanol was then added to the clear lysate, mixed and the mixture 
was transferred to the spin column. The supernatant was then passed through the 
cartridge provided by the kit and washed three times with SV wash solution.   To 
remove DNA contamination, each cartridge was treated with 50μl of DNase incubation 
mix (40μl of yellow core buffer, 5μl of 0.09M MnCl2 and 5μl of DNase I enzyme) and 
incubated at room temperature (20-25°C) for 15 minutes.  
Immediately 200μl of SV DNase stop solution was added to the filter and centrifuge for 
1min. 600μl of SV RNA wash solution was added and centrifuge for 1min. Another 
250μl of SV RNA wash solution was added and centrifuge for 2 mins. The collection 
tube was replaced with a new 1.5ml tube and the purified RNA was eluted with 100µl 
of nuclease-free water. RNA trapped in the membrane was eluted using RNase free 
DEPC treated dH2O. The eluted RNA stored at -70°C. 
 
2.4 Detection of p53 codon 72 polymorphism 
Genomic DNA from blood or tissue was used as a template to amplify human p53 exon 
2 to exon 4 using primers NS11584 For (5’- TCAGACACTGGCATGGTGTT -3’) and 
NS12403 Rev (5’- AAGCCTAAGGGTGAAGAGGA – 3’) as forward and reverse 
primers respectively. PCR condition for a 50 µl reaction was as follows: 940C for 2 
minutes followed by 30 cycles of 940C for 30 seconds, 590C for 1 minute and 720C for 
2 minutes. The reaction was incubated at 720C for 10 minutes for final incubation. 
Amplification was performed using PTC 100TM (MJ Research, USA) used for the PCR. 
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The PCR reaction consisted of: 5µl of 10 X PCR Buffer, 10µl of 5 X Buffer Q, 1µl of 
10mM dNTP mix, 100ng forward primer (NS11584:For), 100ng reverse primer 
(NS12403:Rev) and top up to 50µl with sterile distilled water. The size of the PCR 
product is 800bp. 
 
2.4.1 Purification of PCR product 
The PCR product was run into agarose gel (Low melting agar) and the amplified band 
was excised from the gel. DNA was extracted from this gel fragment using QIAGEN 
(Germany) Gel Extraction Kit according to manufacturer protocol. Briefly, excised gel 
was incubated at 550C in presence of 3 gel volume of Buffer QG for 10 minutes or until 
it was dissolved. One gel volume of isopropanol was added and mix gently. This gel 
mix containing PCR product was passed through gel extraction  cartridge provided and 
wash once with PE wash buffer.  Using distilled water the purified PCR product was 
eluted. 
 
2.4.2 Restriction digestion of PCR product (exon2-4) to detect genotype 
Gel purified PCR product for p53 exon2 to exon 4 was used to detect p53 codon 72 
polymorphism which exist in exon 4.  Restriction analysis was performed using 10μl of 
PCR product, 7μl of dH2O, 2μl of NEB Buffer (10X) and 1μl (10 units/μl) of BstUI 
(New England BioLabs) and incubated at 600C for 3 hours. The p53 arg allele has a 
unique BstUI site (CGCG) that is absent in the pro allele. The digested product was then 
run on a 2% agarose gel to visualize the banding pattern. In case of p53Pro this 
restriction site is absent within this fragment and it remains uncut after BstUI digestion 
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whereas presence of an Arginine residue creates a unique restriction site and it produces 
two bands (600bp and 200bp). Three bands (800bp, 600bp and 200bp) will be found in 
case of heterozygotes.  
 
2.4.3 Sequencing of PCR product  
After detecting the genotype by restriction digestion, the same PCR products were used 
for sequencing to confirm the result. Cycle sequencing performed using 50 to 100ng of 
template, 3pmol of primer and 8µl of Big Dye (Applied Biosystems, USA) in 20µl 
reaction volume. PCR condition is as follows: 30 cycles of 960C for 30 second, 500C for 
15 second and 600C for 4 minutes.  Primers used to sequence p53 exon 2 – 4 region: 
NS 11584 For. 5’- TCAGACACTGGCATGGTGTT – 3’ 
NS 12403 Rev. 5’ – AAGCCTAAGGGTGAAGAGGA – 3’ 
 
PCR-amplified sequencing product was precipitated by sodium acetate-ethanol 
precipitation method. DNA pellet was resuspended in loading dye containing 50mg/ml 
dextran blue + 25mM EDTA and formamide (1:5) which was then denatured at 940C 
for 2 minutes and loaded into 5% acrylamide gel and run in the ABI 377 sequencer 
(Applied Biosystems, USA). Sequences obtained were compared using BLAST 
programme (NCBI) and p53 codon 72 polymorphism was detected. 
 
2.5 One-step RT-PCR to amplify p53 gene  
One step RT-PCR to amplify p53 gene was done using QIAGEN One-Step RT-PCR Kit 
(QIAGEN, Germany). p53 gene specific primers were used here to synthesize first 
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strand cDNA as well as whole p53 gene. The 5’ end of the forward primer starts from 
the start codon of p53 gene and in case of reverse primer the 5’ end starts just after the 
stop codon. The sequences for forward and reverse primers are p53Ex2-For: 5’- 
ATGGAGGAGCCGCAGTCAGATCCTA -3’ and p53Ex11-Rev: 5’- 
GTCTGAGTCAGGCCCTTCTGTCTTGA  -3’ respectively. RT-PCR conditions 
employed was as follows: 30 min and 30 sec at 510C, 15 min at 950C, followed by 36 
cycles of 40 sec at 940C, 1 min at 530C, 1 min 30 sec at 720C and a final extension at 
720C for 8 min.  The resultant PCR product was run into 1.6% agarose gel and 
visualized after staining with ethidium bromide under UV illuminator. The p53 band 
(1.2 kb) was excised and DNA extracted using previously mentioned method.   
 
2.5.1 Sequencing of one-step RT-PCR product (p53 coding region using 5 
primers): 
p53 cDNA obtained from RT-PCR was sequenced using previously mentioned method 
to detect genotype as well as screen for mutation in breast tumor samples. A total of 
five primers which amplify in an overlapping manner in the p53 gene were used for 
cycle sequencing. The sequences of these primers are p53Ex2-For: 5’- 
ATGGAGGAGCCGCAGTCAGATCCTA -3’, p53 (400)-For: 5’- 
TTGCCAACTGGCCAAGAC -3’, p53(600)-For5’- CTTATCCGAGTGGAAGGA -3’, 
p53(800): 5’- AACAGCTTTGAGGTGCGT -3’ and p53Ex11-Rev: 5’- 
GTCTGAGTCAGGCCCTTCTGTCTTGA  -3’. p53 status was analyzed using BLAST 
2 Sequence programme from NCBI website. 
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2.6 Semi-Quantitative One-Step RT-PCR  
To quick check the expression level of Tyrosinase, p21 and 14-3-3σ genes, total RNA 
used for One-Step RT-PCR (QIAGEN) using previously described method. 50 µl of 
reaction volume consists of 10µl of 5X RT-Buffer, 10µl of 5X Buffer Q, 1µl of 10mM 
dNTP and 10µM of each primer. The reaction condition as follows: 
Tyrosinase : 510C for 30min 30sec, 950C for 15min, (940C for 40sec, 520C for 
1min, 720C for 1min 20sec) X 35 cycles, 720C for 10min.  
Size of the PCR product: 750 kb 
14-3-3σ : 510C for 30min 30sec, 950C for 15min, (940C for 35sec, 520C for 
1min, 720C for 50sec) X 25 cycles, 720C for 10min. 
Size of the PCR product: 500bp 
p21/Waf : 510C for 30min 30sec, 950C for 15min, (940C for 30sec, 540C for 
30sec, 720C for 45sec) X 21 cycles, 720C for 10min, Hold at 40C 
Size of the PCR product: 500bp 
 
2.6.1 Semi-quantitative PCR 
Total RNA was reverse transcribed to 1st strand cDNA which used as a template for 
quantitative PCR to quantify the expression of several genes in cell lines that express 
temperature sensitive p53 (TSp53). 5 μg RNA mixed with 1 μg of oligo dT primer 
(NEB) in 10 μl reaction volume, denatured at 700C for 10 minutes and immediately 
chilled on ice for 5 minutes. Reverse transcription reaction was done using 5 units of 
Mlu Reverse transcriptase (NEB), 2μl of 10mM dNTP, 1X RT buffer (NEB) and 1μl of 
10X diluted RNasin (Promega) in final reaction volume of 30 μl and incubated at 370C 
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for 1hour. Finally the reaction mix was incubated at 750C for 10 minutes to inactivate 
the reverse transcriptase. These 1st strand cDNA were used as a template for 
quantitative PCR and number of PCR cycles, annealing temperature and extension time 
were optimized for each gene.  
Primer sequences for different genes are as follows:  
Gapdh-Forward: 5’- ACCCCTTCATTGACCTCAAC -3’ 
Gapdh-Reverse: 5’- CAGCGCCAGTAGAGGCAG -3’  
p53R2-Forward: 5’- ATGGGCGACCCGGAAAGGCCGGAA -3’ 
p53R2-Reverse: 5’- TCTGCATCCAAGGTGAAGACGTT -3’  
p48- Forward: 5’- AGACCTCCGAGATTGTATTACGCCCCA -3’ 
p48- Reverse: 5’- AGATTCCAAAGCTCTTTGCCGTCCATG -3’ 
p53- Forward: 5’- ATGGAGGAGCCGCAGTCAGATCCTA -3’ 
p53- Reverse: 5’- GTCTGAGTCAGGCCCTTCTGTCTTGA -3’ 
Gadd45-Forward: 5’- TTGGAGGAATTCTCGGCTGGAGAGCAGAAG -3’ 
Gadd45-Reverse: 5’- CCATTGATCCATGTAGCGACTTTCCCGGCA -3’  
TRP-1-Forward: 5’- ATGAGTGCTCCTAAACTCCTCTCTCT -3’ 
TRP-1-Reverse: 5’- ACCATTGGTCTGGCCACATTTCCA GCTG -3’  
Tyrosinase-Forward: 5’- TAAGAACCTGATGGAGAAGGAATGCTGTCCA -3’ 
Tyrosinase-Reverse: 5’- TCGGCTACAGACAATCTGCCAAGAGGAGAAG -3’  
Hdm2- Forward: 5’- ATGTGCAATACCAACATGTCTGTACCT -3’ 
Hdm2- Reverse: 5’- AGGGGAAATAAGTTAGCACAATCATTTGA -3’ 
p21- Forward: 5’- ATGTCAGAACCGGCTGGGGATGTCCGT -3’ 
p21- Reverse: 5’- TTAGGGCTTCCTCCTGGAGAAGATCAG -3’ 
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2.6.2 PCR conditions 
TRP-1           :         940C for 2min, (940C for 30 sec, 520C for 30 sec, 720C for 40 sec) 
X 35 cycles, 720C for 8min, Hold at 40C.  
Size of the PCR product: 970bp 
p53 & Hdm2 : 940C for 1min 20sec, (940C for 30 sec, 540C for 40 sec, 720C for 
1min 10 sec) X 24 cycles, 720C for 10min, Hold at 40C. 
Size of the PCR product: 1.2 kb 
Gadd45         : 940C for 1min 30sec, (940C for 25 sec, 530C for 35sec, 720C for 
40 sec) X 23 cycles, 720C for 8min, Hold at 40C. 
Size of the PCR product: 500bp 
p53R2           :  940C for 1min 30sec, (940C for 25 sec, 540C for 40 sec, 720C for 
1min 10sec) X 35 cycles, 720C for 10min, Hold at 40C. 
Size of the PCR product: 1 kb 
p48                : 940C for 3min, (940C for 45sec, 520C for 55sec, 720C for 1min) X 
35 cycles, 720C for 8min, Hold at 40C. 
Size of the PCR product: 700 bp 
Gapdh            : 940C for 3min, (940C for 45sec, 520C for 55sec, 720C for 1min) X 
35 cycles, 720C for 8min, Hold at 40C. 
Size of the PCR product: 500 bp 
 
2.7 Analysis of cell death 
Percentage of apoptotic cells and cell cycle were analyzed using the Fluorescence cell 
sorter (Becton Dickinson, NJ, USA). 
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Cells and culture medium are collected in 5 ml polystyrene round-bottom tube (Becton 
Dickinson, NJ, USA) and centrifuged to pellet down the cells. The pellets were washed 
with 2ml of binding buffer. The pellet was resuspended in 92μl of binding buffer, 5μl of 
Annexin V (FITC labeled, PharMingen) and 40μg/ml of propidium iodide (SIGMA) on 
vortex. The tube is then incubated for 30mins at room temperature in the dark. Another 
400μl of binding buffer  (10mM HEPES/NaOH pH7.4, 140mM NaCl, 2.5mM CaCl2) 
was added to the tube and used for FACS analysis. 
 
2.7.1 Analysis of cell cycle 
Cells were trypsinized and collected in a 5 ml polystyrene round-bottom tube (Becton 
Dickinson, NJ, USA). The tube was then centrifuged using low rpm (500g) to pellet 
down the cells. The supernatant was discarded and the pellet was resuspended in 2ml of 
PBS (1X) while on vortex. This mixture was centrifuged again to pellet down the cells 
and the supernatant was discarded. On vortex, 1ml of 70% ethanol was added in a drop 
wise gradual manner to the tube. The tubes were sealed with parafilm and kept 
overnight at 4°C in the dark. Next day, the cells were centrifuged and the pellet was 
resuspended in 2ml of PBS (1X). The cells were again centrifuged, the supernatant 
discarded and the pellet was resuspend in 500μl- 1ml of PBS (1X) while on vortex. The 
sample was treated with 100μg/ml RNase A (QIAGEN) for 1 hour at room temperature. 
50μg/ml propidium iodide was added just before FACS analysis. The sub-G1 DNA 




2.8 Luciferase reporter assay 
pGL3 basic vector (Promega, USA) with luciferase reporter gene driven by different 
promoter of p53 target genes were used. Luciferase construct containing TRP-1 and 
Tyrosinase gene promoter was obtained from Dr K Nylander (Umeä University, 
Sweden), p53R2 and p53AIP promoter containing constructs were obtained from Prof 
H Arakawa (University of Tokyo, Japan) and Bax, p21 and Mdm2 promoter containing 
constructs were obtained from A/Prof K Sabapathy (National Cancer Centre, 
Singapore).  
 
1.5X105 cells per well were splitted in six-well tissue culture plate and after 24 hours 
they were transfected with luciferase construct (500 ng per plate) along with wild type 
or mutant p53 (10 ng, 50 ng, 100 ng and 500 ng per plate). All of the experimental units 
were co-transfected with β-gal (500 ng) containing vectors to normalize transfection 
efficiency. After different time point, transfected cells were lysed with lysis buffer (1% 
Triton X-100, 25mM Glycylglicine, 15mM MgSO4, 4mM EGTA and 1mM DTT) and 
spin down for 30 minutes at 40C. The supernatant was then used to measure luciferase 
as well as β-gal expression using Luminometer (Lumat LB9507, EG & G 
BERTHOLD). Each experiment was done in replication.  
 
2.8.1 Luciferase Assay 
50 –100 µl of lysate were mixed with 300µl of lucifearse assay buffer (25mM 
Glycylglicine pH7.8, 5mM ATP, 15mM MgSO4, 1mM DTT) in a polystyrene round-
bottom 5ml tube (Falcon). Injecting buffer contain 25mM Glycylglicine and luciferin 
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(D(-)-Luciferin, Boehringer Mannheim GmbH, Germany) which is a substrate of 
luciferase was added separately. When cell lysate along with luciferase assay buffer 
come in contact with injecting buffer, the luciferase acts on luciferin and produce 
chemiluminescence that is measured by the luminometer.  
 
2.8.2 β-gal Assay 
80 –100 µl of lysate mixed with 200µl of β-gal assay buffer containing 100mM Sodium 
phosphate pH8.0, 1mM MgCl2 and 10% Galacton (TROPIX, Bedford, MA, USA) in a 
polystyrene round-bottom 5ml tube (Falcon) and incubated at room temperature for 1 
hour in dark. Injecting buffer containing 10% Emerald (TROPIX, Bedford, MA, USA) 
and 200mM NaOH was added separately. When both cell lysate along with β-gal assay 
buffer come in contact with injecting buffer, it produces chemiilluminiscence that is 
measured by the luminometer.  
 
2.8.3 Host-cell reactivation assay 
Host-cell reactivation assay was done to investigate the efficiency of DNA repair by 
two wild type p53 polymorphic forms. DNA damage was induced to pGL3 luciferase 
construct by UVB or gamma irradiation and was co-transfected along with wild type 
p53 in different cell lines. These cell lines were cultured to allow repair of damaged 
DNA (pGL3, Promega) and the luciferase activity were measured. High luciferase 




2.9 Western blotting 
Cellular proteins were isolated by lysing cells in protein extraction buffer (10mM NaCl, 
0.5% NP-40, 10mM  Tris-HCl pH 7.4, 3mM MgCl2, 0.5 mM PMSF) in presence of 
protease inhibitor cocktail (SIGMA) and incubating on ice for 1 hour. The lysate was 
centrifuged at 10000g (40C) for 30 minutes and supernatant containing soluble protein 
was collected. Proteins were quantified by Bradford Assay using BSA as standard. 
Proteins were denatured in 6X loading dye (2%SDS, 10mM DTT, 60mM Tris pH8.0, 
1% bromophenol blue and 15% glycerol) before performing SDS-PAGE. Depending on 
the size of proteins detected, different percentage of SDS-PAGE have been used. The 
stacking gels were prepared using Bis acrylamide (Bio-Rad), stacking gel buffer (0.5 M  
Tris-HCl pH 6.8, 0.4% SDS), 10%APS and TEMED. Separating Gels were prepared 
using bis-acrylamide (bio-rad), separating gel buffer (0.5 M  Tris-HCl pH 8.7, 0.4% 
SDS), 10% APS (freshly made) and TEMED (Invitrogen). After electrophoresis the 
separated proteins were transferred by electroblotting (40V, 12 hours at 40C) on to a 
PVDF membrane (Millipore, USA). Protein transfer was always checked by staining 
the membrane with Ponceau Red (BioRad). The membrane was blocked in 1X TTS 
(10mM Tris-0.15 M NaHCl pH 7.6) and 5% non-fat milk for 1-2 hours at room 
temperature. After washing with wash buffer (1X TTS, 0.2% Tween 20 and 0.5% 
nonfat milk) for three times (10 minutes each) in an orbital shaker the blot was 
incubated with commercially available protein specific primary antibody for 2 hours at 
room temperature or 40C for overnight. After several wash (3 times) the blot was 
incubated in secondary antibody (anti mouse/rabbit IgG) conjugated to horseradish 
peroxidase for 1 hour and the ECL non-radioactive detection system (Amersham) was 
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utilized to detect the antibody-protein complexes by exposure of the membrane to 
Kodak X-Omat autoradiography film.  
 
2.10 Measuring melanin content 
Human melanoma cells were counted using either Haemocytometer (SIGMA) or Cell 
counter (Sysmex CDA 5000, Sysmex Corporation, Kobe, Japan) and equal number of 
cells for each experimental unit was lysed in 1M NaOH or Soluene (SIGMA). Once the 
cells are dissolved the lysate was used to measure melanin contents using 
spectrophotometer (Amersham Bioscience) at OD590. Synthetic melanin (Sigma-
Aldrich, Cat: M2649) was used as a standard (0.1μg, 0.2μg, 0.5μg, 1.0μg, 1.5μg, 2.0μg, 
3μg, 5μg). 
 
2.11 Generating p53 mutants using SDM  
PCR based Site Directed Mutagenesis (SDM) was performed to prepare p53 mutant 
forms with 50 ng plasmid (pCDNA3-p53 or pBabe-p53), 1 μl of 10mM dNTP, 100 ng 
of both forward and reverse primers, 1X Pfu Buffer (Promega) and 5 units of Pfu 
polymerase (Promega) in 50 μl reaction. PCR condition was as follows: 950C for 
2minutes, 15 cycles of denaturing at 950C for 1 minute, annealing at 540C to 580C 
(depending on Tm of the primers), extension at 680C for 14 minutes; and a final 
exiension at 680C for 15 minutes. The PCR products were digested with methylation 
specific restriction enzyme DpnI to remove the parental (template) DNA leaving only 
the mutation induced PCR-amplified DNA.   
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2.11.1 Following primers were used for SDM 
p53 codon 72 proline to p53 codon 72 arginine (CCC to CGC): 
For: 5’- AGAGGCTGCTCCCCGCGTGGCCCCTGCA -3’ 
Rev: 5’- TGCAGGGGCCACGCGGGGAGCAGCCTCT –3’ 
p53 - 175 (Arginine to Histidine: cgc to cac ): 
For: 5’-  GACGGAGGTTGTGAGGCACTGCCCCCACCATGAG –3’  
Rev: 5’- CTCATGGTGGGGGCAGCGCCTCACAACCTCCGTC –3’ 
p53 - 245 (Glycine to Serine:  ggc  to agc ): 
For: 5’- C CTGCATGGGCAGCATGAACCGGAG –3’  
Rev: 5’- CTCCGGTTCATGCTGCCCATGCAGG –3’    
p53 - 248 (Arginine to Tryptophan: cgg  to tgg ): 
For: 5’-  CGGCATGAACTGGAGGCCCATCCTC –3’  
Rev: 5’- GAGGATGGGCCTCCAGTTCATGCCG –3’ 
p53 - 249 (Arginine to Serine:, agg to agt ): 
For: 5’- GGGCGGCATGAACCGGAGTCCCATCCTCACCATCATC –3’ 
Rev: 5’- GATGATGGTGAGGATGGGACTCCGGTTCATGCCGCCC –3’ 
p53 - 273 (Arginine to Histidine: cgt  to  cat ): 
For: 5’- CTTTGAGGTGCATGTTTGTGCCTGTC –3’   
Rev: 5’- GACAGGCACAAACATGCACCTCAAAG –3’ 
p53 - 282 (Arginine to Tryptophan: cgg to tgg ):          
For: 5’- CCTGGGAGAGACTGGCGCACAGAGG –3’  
Rev: 5’- CCTCTGTGCGCCAGTCTCTCCCAGG –3’ 
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2.11.2 Temperature sensitive p53 
Temperature sensitive p53 forms were generated by inducing a point mutation at amino 
acid 143 (valine to alanine) and amino acid 138 (alanine to valine) residues of p53 gene 
using SDM. These p53 forms are inactive or mutant conformation at 370C or 390C but 
they act as wild type at 320C. Following primers were used to generate temperature 
sensitive p53: 
p53 aa 138- alanine to valine: 
For: 5’- TGTTTTGCCAACTGGTCAAGACCTGCCCTGTG -3’ 
Rev: 5’- CACAGGGCAGGTCTTGACCAGTTGGCAAAACA -3’ 
p53 aa 143- valine to alanine: 
For: 5’- CAAGACCTGCCCTGCGCAGCTGTGGGTTG -3’ 
Rev: 5’- CAACCCACAGCTGCGCAGGGCAGGTCTTG -3’ 
 
2.12 Preparing competent cell: 
E coli strain XL-1 Blue (Stratagene) has been used for bacterial transformation. To 
prepare competent cell, single bacterial colony was inoculated in 5 ml of LB broth and 
grown in shaker at 370C for overnight. 1ml of this culture was inoculated in 200ml of 
LB broth and grown until the OD600 reached to ~0.45. The culture was the centrifuged 
at 1000g for 10 minutes at 40C to collect the bacterial cells. These were re-suspended in 
ice cold CaCl2 solution (60mM CaCl2, 15% glycerol and 10mM PIPES) and spin down 
for three times (400g, 5 minutes) to wash. Finally the bacterial cells were re-suspended 
very gently in CaCl2 solution and kept at -800C or used for transformation.  
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2.12.1 Bacterial transformation  
5μl of SDM-PCR products were mixed with 50 μl of competent cell and kept on ice for 
15 minutes, heat-shocked at 420C for 2 minutes and quickly chilled on ice for 10 
minutes. 1 ml of LB broth was added to the tube and incubated at 370C in a shaker for 1 
hour to grow newly transformed bacteria. The culture was then plated on LB agar plate 
containing 100μg/ml ampicillin and incubated at 370C for overnight.  
 
2.12.2 Large scale preparation of plasmid DNA (Maxiprep): 
Plasmid DNA was isolated using QIA Maxiprep Kit (QIAGEN). Single colony was 
picked up and inoculated in LB broth medium and cultured overnight. 250ml culture 
was centrifuged to pellet bacterial cells and then resuspended in 10ml of resuspension 
buffer P1 (with RNase). 10ml of lysis buffer P2 were added and allowed to lyse 
bacterial cell for not more than 5 minutes at room temperature. 10ml of neutralizing 
buffer P3 added and mix immediately by inverting the tube gently for several times and 
centrifuged for 30 minutes at 10000g, 40C to remove cell debris. The supernatant was 
filtered using QIA filter and pass through cartridges to allow DNA to bind to the 
membrane. After washing with wash buffer the DNA was eluted in 10ml of elution 
buffer. DNA was precipitated at room temperature for 10 minutes by adding 15ml of 
isopropanol. After centrifuging at 10000g for 15 minutes (40C), DNA pellet was found 
and washed with 70% ethanol. The DNA pellet was then dried and resuspended in 
either TE buffer or distilled water. All plasmid constructs were sequenced to check for 
the induction of mutation.  
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2.13 Unscheduled DNA synthesis: 
Equal numbers of cells from different cell lines were plated in 96-well flat bottom plate. 
20 mM of hydroxyurea (SIGMA) added to the culture to eliminate cells from S-phase 
and cells were kept at 320C for one hour before UV treatment to activate p53. Different 
doses of UV (25J/m2 and 50J/m2) were used to induce DNA damage and cultures were 
allowed to repair damaged DNA in presence of 15 μci/ml of 3H and 20μM of 
hydroxyurea. Cells were then transferred to blot using cell harvester. The blot was dried 
briefly and immersed in scintillation fluid after transferring the blot into a plastic 
pouch/bag. Incorporation of 3H during unscheduled DNA synthesis was measured using 
scintillation counter. 
 
2.14 South-Western analysis 
Equal amount of genomic DNA from cells were diluted to 10μl with 2XSSC (final 
concentration) and blotted on a nylon membrane followed by UV cross linking to fix 
DNA onto the membrane. The blot was blocked for one hour at room temperature and 
incubated with anti-thymidine mouse monoclonal antibody (Kamiya, USA) and 
detected with anti mouse IgG horseradish peroxidase labeled secondary antibody 
(SIGMA). Blocking solution, wash buffer and detection process were the same as for 
western blotting.  
 
2.15 Micronucleus Analysis 
Cells were treated with gamma irradiation and cultured for 7 hours to allow repair of 
damaged DNA. Cytochalasin B (5μg/ml) was then added to prevent cytokinesis at 
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telophase. After 22 hours of culture, cells were trypsinized and transferred into conical 
tube. After removing trypsin, 5ml of cold (40C) hypotonic buffer (0.075M KCl) was 
added to the tube very slowly while vortexing gently. These were immediately 
centrifuged at low rpm (800 rpm for 8 minutes). The supernatant was removed carefully 
and cells were fixed with cold methanol: acetic acid (3:1) while on vortex and spin 
down for 8 minutes at 800 rpm. To preserve the cytoplasm, 3 to 4 drops of 
formaldehyde was added and mixed with cells very gently and the cells were washed 
with cold fixative reagent (methanol: acetic acid, 3:1) for three times and finally cells 
were resuspended in 500 μl of fixative reagent and kept at 40C until they were observed 
under microscope.  
50μl to 100μl of acridine orange solution (0.03mg/ml in 1X PBS) added to the slide and 
under fluorescence microscope using DAPI/FITC/TRITC filter.  
 
2.16 Immunoprecipitation  
p53 wild type conformation at 320C or 370C was checked by wildtype conformation- 
specific antibody. p53 protein was inmmunoprecipitated with wild type conformation 
specific antibody pAb1620 (CALBIOCHEM). The reaction volume was top up to 500 
µl with protein extraction buffer (10mM NaCl, 0.5% NP-40, 10mM Tris-HCl  pH 7.4, 
3mM MgCl2).  
200 µg of protein mixed with 0.3µg of antibody and immunoprecipitated at 40C for 
overnight on a rotator. 20 µl of mouse IgG –specific secondary antibody with agarose 
beads (SIGMA) was added and incubate on the rotator at 40C for 2hours. The reaction 
was spin down at low rpm (3000rpm) at 40C to pellet agarose beads containing protein-
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antibody complex. This was washed 3 times with extraction buffer at 40C. The 
precipitated proteins were used for SDS-PAGE using previously descried method and 
p53 protein conformation analyzed.  
 
2.17 DNA and Tissue samples 
The study included 400 Asian healthy subjects (160 Chinese, 96 Malay and 144 
Indians), about 88 Chinese breast cancer samples and 105 Polish healthy subjects.  The 
materials were used upon written consent by the patients, according to the ethics 


















Chapter 3. Results 
3.1 Distribution and expression of p53 codon 72 polymorphic variants 
3.1.1 Distribution of the p53 polymorphism in Singapore   
We have analyzed the status of the codon 72 p53 polymorphism in Chinese, Malay and 
Indian population in Singapore using DNA from peripheral blood of healthy donors. 
The distribution of this p53 polymorphism in the three different races is different.  The 
frequency of p53Arg (arg) allele is higher in Chinese population relative to other two 
races, while p53Pro (pro) is more predominant in Indian population. The frequencies of 
the polymorphic alleles are shown in (Figure 1 A & B).   
 
The genotype frequency of arg/arg homozygotes was highest in the Chinese (35.17%), 
but lower in the Malays and Indians (23.95% and 20.83%, respectively).  In contrast, a 
higher proportion of the Indians and Malays were found to be pro/pro homozygotes 
(31.94% and 33.33% respectively) compared to the Chinese (22.75%).  Similarly, the 
frequency of the p53Arg allele was highest in the Chinese whilst that of the pro allele 
was highest in the Malays and the Indians.  The frequency of heterozygotes was similar 
in Chinese and Malays (42.06% and 42.71% respectively) but higher in Indians 
(47.22%) (Figure 1A). Pair wise interethnic comparison revealed the Chinese to be 































































Fig 1. Distribution of p53 codon 72 polymorphism in Singaporean population. 
Figure (A) shows percentage of p53 codon 72 polymoprhism in three different races as 


































3.1.2 Expression of the p53 Codon 72 allele in Healthy Heterozygotes  
3.l.2.1 Expression of p53 allele in Chinese Healthy Heterozygotes. 
Since there is an association of p53Pro and p53Arg with ethnic groups and a large 
number (around 50%) of them are heterozygotes, we were interested to investigate the 
expressing allele of p53 in these individuals. Peripheral blood genomic DNA from 160 
Chinese and 105 Polish healthy donors was used to initially determine the genotype by 
BstUI restriction digestion, as well as sequencing, to identify p53Pro/p53Arg 
heterozygotes (Chapter 2.4.1 to 2.4.4). Two independent methods were used to 
determine the degree of the expression of the various alleles: the PCR-RFLP method 
and the sequencing method. We first did reconstitution experiments using varying ratios 
of the p53 pro mRNA and p53 arg mRNA as templates in restriction enzyme digestion 
and sequencing analysis to rule out the lack of sensitivity that might lead to the 
preferential detection of either the pro or p53Arg alleles (Figure 2A and 2B). We found 
that the presence of even 10% to 20% of either pro or arg in the total template mixture 
could be detected by restriction digest analysis (Figure 2A) and by sequencing (Figure 
2B, arrows pointing to traces of the peaks), indicating that unequal and varying 
expression of both alleles can be detected by the methods employed in this study. Using 
these methods, mRNA was prepared from 25 Chinese heterozygote samples and 
expressing allele of p53 was detected. Most of the samples (80%) were found to express 
the p53Pro allele and 20% expressed both the p53Pro and p53Arg alleles 
(representative samples shown in Figure 3A and 3B). However, there was a distinct 
absence of the preferential expression of the p53Arg allele in the healthy Chinese 




































Figure 2. Determination of sensitivity of the sequencing method to detect 
expressing allele of p53. 
p53Pro and p53Arg mRNA were mixed in different ratio (as indicated) and after reverse 
transcription followed by PCR, the samples were digested with BstUI and run into 
agarose gel (A). Size of the bands: pro/pro = 750bp; arg/arg = 280 and 220bp; arg/pro = 
750,500,280 and 220bp. The same PCR products were subjected to sequence analysis 
for determination of the codon 72 of p53. The arrows indicate the presence of the 
different peaks (G or C). Both the peaks are detectable even at the lowest ratio of 
p53Pro and p53Arg (10%: 90%), indicating the sensitivity of this method in revealing 













































Figure 3. Expression of p53 alleles in Chinese healthy heterozygotes.  
A). Number of expressing alleles of p53 in Chinese healthy heterozygotes. 
B). Electrophenogram of mRNA (cDNA) from the heterozygote samples shows 









Figure 3, continued. Expression of p53 alleles in healthy Europeans. 
 
C). Number of samples analyzed. 
D). Electrophenogram shows higher expression of p53Arg allele (indicated by arrow).  
 
























In some of the heterozygote samples that expressed the p53Pro allele, even minute 
amounts of the G nucleotide encoding for p53Arg allele was not detectable, indicating 
selective expression of the p53Pro allele (Figure 3B, arrows).  
 
3.1.2.2 Expression of p53 allele in European Healthy Heterozygotes 
To analyze the expression of p53 allele in European population, 48 Polish healthy 
heterozygotes mRNA were analyzed and the status of the p53 expressing allele was 
determined.  It has been found that most of the Polish heterozygotes (60%) expressed 
the p53Arg allele or expressed both the p53Arg and p53Pro alleles (Figure 3C and 3D). 
In p53Pro/p53Arg expressers, the G nucleotide forming part of the arginine codon was 
always higher than C counterparts (Figure 3D).  
 
3.1.2.3 Comparison of Expression of p53 allele in Chinese and European Healthy 
Heterozygotes 
The normal genotype frequency of p53 codon 72 polymorphs in Chinese population is 
similar to that of European population (Figure 1, Beckman et al., 1994). However, the 
expression of these alleles in heterozygotes shows that these populations express two 
alleles differentially and there may be a selection pressure that controls their expression. 
The normal distribution of this polymorphism shows that frequency of p53Pro is higher 
in Population near Equator, whereas that of p53Arg is higher in Europeans. Hence, we 
hypothesize that since Singapore is in Equatorial region (10N of the Equator) and 
p53Pro is predominant, so the heterozygotes tend to follow the normal distribution of 
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the genotype in their expression level. Similarly, heterozygotes in Europeans tend to 
express p53Arg which is predominant in that population (Figure 3C).  
 
3.1.3 Expression of the p53 allele in breast cancer tissues 
Since we have observed that there is a preference of expression of p53 codon 72 alleles 
in healthy Chinese heterozygotes, we investigated if there was a correlation between 
susceptibility to cancer and the expression status of p53 polymorphism. Ninety four 
Chinese breast cancer patient samples and the adjacent, histologically normal epithelial 
tissues for some samples were screened extensively for mutations in the entire coding 
region of the p53 gene, as well as for the expression status of the polymorphic variants 
at codon 72.  
 
3.1.3.1 p53Arg was higher in heterozygote breast cancer tissues than healthy 
subjects  
Allelic expression status analysis revealed that many of the heterozygote samples (15 
p53Arg/p53Pro samples analyzed) preferentially expressed the p53Arg allele (Figure 
4A and 4B), which was in contrast to the data obtained in healthy subjects (Figure 3A). 
These heterozygote p53Arg expressers show low or no traces of the expression of the 
p53Pro allele (Figure 4B). This suggests that the p53Arg allele may be selectively 
activated in this population and the p53Pro allele is down regulated in the 
heterozygotes. It has been observed that 68% of the heterozygotes preferentially 
expressed the p53Arg allele, which was in contrast to the healthy population where 
p53Arg expression was absent (Figure 4B). 
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We have excluded the possibility of loss of heterozygosity (of the p53Pro allele) in the 
heterozygotes as a possibility for the selective expression of the p53Arg allele. Because 
all the samples were sequenced and DNA sequencing analysis showed that both C and 
G nucleotides are present (Figure 5B).   
 
3.1.3.2 Histologically normal tissues from Chinese breast cancer patients 
preferentially express the p53Arg allele 
p53 expression status in the corresponding adjacent histologically normal tissues of 
some of the heterozygote cancers was analyzed. This analysis showed that histological 
normal tissue either express p53Arg alone or p53Arg and p53Pro. Interestingly, there 
was no expression of the p53Pro allele in these samples  (Figure 5A and 5B). This 
observation is in contrary with the expression of p53 allele in peripheral blood in 
healthy heterozygotes and breast tissue of two healthy heterozygote donors (Figure 5B, 
bottom). This type of selective of the p53Arg allele in the histologically normal adjacent 
tissues in breast cancer suggests that expression of p53 allele may have association with 
breast cancer susceptibility. 
 
3.1.4 Mutational status of p53 in breast cancer 
Since 50% of all human cancers carry mutations in p53, the mutational status of the p53 
gene in breast cancer samples was evaluated.  Mutations were significantly reduced and 
detected in only 31% of p53Arg-expressing tumor samples whereas about 55% of the 
p53Pro-expressing cancer samples had a mutation in the p53 gene (Figure 6A, P = 
0.037). One p53 hotspot, aa248 was found mutated in 38% of total samples. Followed 
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by aa80 which account for 13% of total mutation (Figure 7). The data show that in 
p53Arg form, mutations are found all over the p53 gene. In contrast, mutations in 
p53Pro form are mainly confined to the DNA binding domain, except for two mutations 
found in the proline rich domain (Figure 6B). Detailed analysis revealed that 63% of all 
the mutations in the arg-expressing samples were recessive mutations that were 
predominantly found outside the DNA-binding domain of p53 (Figure 6B).  
Interestingly, most of the p53Pro-expressing tumours carried mutation in the DNA-
binding domain which are considered dominant mutations in p53, whereas all the 
mutations in p53Arg were found outside the DNA binding domain. This indicates that 
p53Pro form may require a strong (dominant) mutation to become inactivated, whereas 



























































Figure 4. Cancer tissues from Chinese p53Pro/p53Arg patients preferentially 
express p53Arg allele. 
 
A). RT-PCR was done to amplify p53 and analyzed by restriction digestion using 
BstUI. Heterozygote Chinese patients show increased expression of the p53Arg allele. 
A 500bp band for p53Pro allele, 210 and 169 for p53Arg allele. 
 
B). Ratio of p53Arg/p53Pro expression in cancer samples. The ratio of p53Arg/p53Pro 
allele expression was determined as described from 25 healthy and 15 cancer 
heterozygote samples. The percentage of people preferentially expressing the pro allele 
is significantly higher than the preferential p53Arg expressers in the healthy normal 
population whereas the percentage of people preferentially expressing p53Arg allele in 
the cancer population was significantly higher than the normal population. 
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Figure 5. Preferential expression of p53Arg allele in heterozygote (p53Pro/p53Arg) 
breast cancer tissue. 
 
A). mRNA expression analysis by RT-PCR followed by restriction digestion with BstUI 
shows the expression of p53Arg allele in breast cancer and healthy heterozygotes.  
 
B). Sequence analysis of the RT-PCR product (p53 cDNA) from the heterozygotes in 
breast cancer shows that both alleles are expressed and this exclude the possibility of 








Figure 6. Status of p53 mutation in breast cancer samples. 
 
A). Comparison of the number of p53Pro- or p53Arg-expressing breast cancer samples 
with or without a mutation in the p53 gene. The number of p53Arg-expressing patients 
without a mutation in the p53 gene is significantly more than those with a mutation (P = 
0.037, exact test).  
 
B). Distribution of p53 mutations in breast cancers. The top line indicates the p53Arg 
allele and the lower part indicates the p53Pro allele in the breast cancer samples, and 
the frequency of mutations is indicated as length of the bars (not to scale).  
The frequency of mutation at codon 248 was 38% and at codon 80 was 13% among the 
































































Figure 7. Percentage of type of mutation in p53 in breast cancer samples.   
 
Frequency of mutation in different amino acid residues in p53 in Chinese breast cancer 
population. 39% of these mutations at aa248 and 13% at aa80 residues (left: mutated 
amino acid residue and right: percentage of mutation detected). 
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3.2 Significance of p53 polymorphism, properties and functions    
3.2.1 Role of p53 polymorphs in DNA repair 
Active p53 can induce apoptosis, cell cycle arrest and DNA repair by which it maintains 
genomic integrity. So, it can be predicted that the difference to induce those functions 
by these two p53 polymorphs may cause different types of abnormalities and these two 
p53 polymorphic variants may associate with those abnormalities or cancers.  
It has been shown that p53 codon 72 polymorphism affects p53’s role in apoptosis and 
cell cycle arrest; p53Arg form is more efficient in inducing apoptosis (Dumont et al., 
2003) and the p53Pro form induces G1 arrest more efficiently than p53Arg (Pim and 
Banks, 2004). Since DNA repair is one of the important mechanism in mammalian cells 
to maintain genomic integrity, we were interested to investigate the difference, if any, in 
repair efficiency by these two p53 polymorphic variants.  
 
It is well established that DNA of the skin is the central target of UVB. When skin is 
exposed to sunlight, the UVB (solar UV) induces cyclobutane pyrimidine dimers or 
CPDs (Ravanat et al., 2001). To protect the skin, epidermal cells should remove CPDs 
by nucleotide excision repair (Yarosh et al., 1991). Defects in CPD removal pathway 
are thought to be involved in sunlight-induced melanogenesis (Gloster & Broadland, 
1996). Since p53 polymorphs has association with skin cancer (de Oliviera et al., 2004), 
we speculate that p53 codon 72 polymorphism may play a differential role in DNA 
repair via nucleotide excision repair (NER).  
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3.2.2 Regulation of p53 dependent DNA-repair target gene promoters by p53Pro 
and p53Arg variants 
An initial series of luciferase reporter assay were carried out to investigate if the p53 
variants are capable of differentially regulating p53-dependent DNA-repair gene 
promoters.  
 
3.2.2.1 Expression of Gadd45 promoter in presence of either p53Pro or p53Arg 
First evaluated was the effect of p53Pro and p53Arg on the Gadd45 promoter-luciferase 
construct. H1299 human lung cancer cell line (ATCC) which does not have endogenous 
p53 has been used to observe the Gadd45 promoter activation in presence of 0.5μg of 
either p53Pro or p53Arg.  48 hours after transfection, the average relative luciferase unit 
(RLU) in p53Pro, p53Arg and empty vector was 32.44 (32.9, 32), 22.80 (22.6, 23) and 
0.80 (0.8, 0.8) respectively (Figure 8A). In one experimental unit, only Gadd45 carrying 
plasmid was transfected as a negative control and the background RLU was as low as 
vector control (0.7, 0.8), suggesting the validity of the experiment (8A, right). In the 
same cell line three different concentrations of p53; 0.05μg, 0.1μg and 0.2μg were used 
and results show that p53Pro form consistently induces Gadd45 promoter activation 
more than p53Arg form. The RLU for these experiments as follows: 
For 0.05μg: p53Pro = 44.9 and 40.69, p53Arg = 34.83 and 24.11, and empty vector = 
0.52 and 0.40. For 0.1μg: p53Pro = 46.33 and 41.47, p53Arg = 27.6 and 29.71, and 
empty vector = 0.44 and 0.50. For 0.2μg: p53Pro = 58.52 and 59.07, p53Arg = 31.57 
and 24.8, and empty vector = 0.53 and 0.53 (Figure 8B). 
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Finally, another series of experiment was done in SAOS-2 cell line with or without UV 
irradiation at 40J/m2.  In untreated experiment RLU for p53Pro, p53Arg and vector was 
78.89, 30.59 and 2.68 respectively (Figure 8C, left). After 24 hours of post-transfection 
cells were treated with 40J/m2 UV and luciferase assay was done after another 24 hours. 
Average Gadd45-Luc expression in p53Pro, p53Arg and vector was 26.06 (24.39, 
27.72), 12.86 (11.32, 14.4) and 2.89 (2.57, 3.21) respectively (Figure 8C, right).  
 
3.2.2.2 Expression of p53R2 promoter 
High expression of Gadd45 promoter in the presence of p53Pro form was consistent. 
We then investigated the promoter activation of another p53-targeted DNA repair gene 
p53R2 in presence of p53Pro or p53Arg. Similar experiment was done in p53 null 
mouse embryonic fibroblast (MEF) and human oesteosarcoma (SAOS-2) cell line with 
low amount of p53 (10 ng, 50 ng and 100 ng) (Figure 9A and 9B).  
Consistently, the p53R2 promoter shows higher activation in presence of p53Pro than 










3.2.2.3 Expression of p53 target gene promoters as a control  
This experiment was done in order to rule out any artifact that may affect the reporter 
assay. p53 can transactivate p21 and p53AIP-1 upon activation and these genes are not 
directly related to DNA repair. The experiment showed that in SAOS-2 cell line both 
p53Arg and p53Pro were capable of activating the p21 and p53AIP-1 promoters to 
similar extents and no significant differences were observed (Figure 10 A and 10B). 






























































































































0.05μg                  0.1μg                      0.2μg 
 
Figure 8. Expression of Gadd45 promoter in H1299 cell line (A) and Saos-2 cell 
line (B) in presence of  different concentration of two p53 polymorphs, 48 hours 
after transfection.  
Each experiment was done in duplicates (series 1 and 2). 
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Figure 8, continued. 
 
C). Expression of Gadd45 in Saos-2 cell line. 













































































































10 ng              50 ng       100 ng 
 
Figure 9. Expression of p53R2 promoter in presence of p53Pro or p53Arg form. 
 
A). Expression p53R2 promoter in MEF (0.5μg DNA used). 
B). Expression of p53R2 promoter in SAOS-2 cell line with three different amount of 
DNA as indicated.  































































Figure 10. Luciferase reporter assay in SAOS-2 cell line shows that p21 (A) and 
p53AIP-1 (B) express equally in p53Pro and p53Arg form.  





































3.2.3 p53 inducible gene expression in isogenic cell lines expressing the p53Arg or 
p53Pro form 
In an attempt to investigate the physiological consequences of the differential activation 
of target gene promoters by p53Pro and p53Arg, isogenic cell lines expressing these 
two variants of p53 under inducible condition have been generated. Since transfection 
of active p53 in a cell results in cell death, it is necessary to express p53 in an inducible 
condition. To investigate the properties of the p53 polymorphs, temperature sensitive 
p53Pro and p53Arg forms were made by site-directed mutagenesis (SDM) and 
confirmed by sequencing. The eukaryotic expression vector pCDNA3 containing a 
neomycin selection marker was used. Two temperature sensitive p53 mutants were 
independently made: amino acid 143 (valine to alanine at amino acid residue 143) or 
amino acid 138 (alanine to valine at amino acid residue 138). These temperature 
sensitive p53 forms are mutant or inactive at 390C, and they become active or wild type 
at 320C. 
 
3.2.4 DNA repair assay using temperature sensitive-isogenic stable cell lines  
p53 null H1299 (lung cancer) and UISO (melanoma) cells were transfected with 
temperature sensitive p53Arg or p53Pro plasmids and stable cells were generated. The 
temperature-sensitive p53 variants are active at 320C and inactive at 390C (Michalovitz 
et al., 1990). Cells from the 138 temperature-sensitive panels expressing equal amounts 
of p53 both at the RNA and protein level were used in the subsequent experiments 
(Figure 11A and 11B). Similar data were obtained throughout with 143 temperature-
sensitive cell lines (data not shown). Consistent with an earlier observation (Thomas et 
al., 1999), immunoblot assay shows p53Arg form migrates faster than p53Pro form in 
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SDS-PAGE (Figure 11B). Using these cells, the induction of p53 target genes; Hdm-2 
and p21 was evaluated subsequent to temperature shift. Both cell lines (with either 
p53Pro or p53Arg) induce Hdm-2 gene expression but not by the empty vector (Figure 
11A, middle). Expression of p21 was induced at 320C, as detected by semi-quantitative 
RT-PCR (Figure 11C) and immunoblot assay (Figure 11D), indicating that both the cell 
types expressing the temperature sensitive p53 variants are functional and active at this 
permissive temperature. However, there were no significant differences in expression of 
these target genes between the p53Arg- and p53Pro-expressing isogenic cell lines.  
 
3.2.4.1 Apoptosis induce by temperature sensitive p53- isogenic cell lines 
A temperature shift to 320C results in the activation of p53 in these cell lines and this 
induces apoptosis and the percentage of cell death was: vector vs.p53Pro vs. p53Arg: 
18% vs. 16% vs. 30% respectively (Figure 12). These results are consistent with 
previous findings that p53Arg has a greater potential to induce apoptosis than p53Pro 
(Dumont et al., 2003), and together confirms that the isogenic cell systems are 
functional. 
 
3.2.4.2 p53 dependent DNA-repair genes are differentially regulated by p53Pro- 
and p53Arg expressing isogenic cell lines 
Next it was evaluated if the p53-dependent DNA-repair target genes are differentially 
regulated in the isogenic cell systems. H1299 cells were shifted to permissive 
temperature and expression of Gadd45, p53R2 and p48 was monitored at various time-
points. None of the targets genes were activated at 390C (Figure 13 and 14). All these 
genes were expressed within 30 min to 2 hours of post-temperature shift at 320C. 
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Figure 11. Generation and characterization of isogenic cell lines expressing p53Pro 
and p53Arg.  
 
p53 null H1299 cells were transfected with vector, temperature sensitive p53Pro (Pro) 
or p53Arg (Arg) plasmids and stables cells were generated. All cells were grown at 
390C and 320C and the expression of p53 and its target genes were detected. 
A).Semi-quantitative RT-PCR shows expression of p53 and Hdm2. 
B). Expression of p53 protein detected by immunoblot. 
C). Semi-quantitative RT-PCR expression level of p21. 




















































Figure 12. Generation and characterization of isogenic cell lines expressing p53Pro 
or p53Arg. 
 
Spontaneous cell death was determined in the various H1299-based isogenic cell lines. 
Cells were cultured at 390C or 320C for 36 hrs before analysis. Cell death was 








3.2.4.3 Gadd45 expression 
Expression of Gadd45 was measured by semi-quantitative RT-PCR in different time 
points of shifting at 320C with UV. Gadd45 levels were always higher in p53Pro 
expressing cells than p53Arg counterparts (Figure13A). RT-PCR products were run into 
agarose gel and the gel photo was analyzed using Gel.Doc software (BioRad) to 
quantify the intensity of bands. Data show that expression of Gadd45 always higher in 
p53Pro cells.  
 
3.2.4.4 Induction of p48 by two p53 polymorphic variants 
p48 plays an important role in nucleotide excision repair (NER) and this gene can be 
transactivated by wild type p53. Since it has been observed that p53Pro form induces 
more expression of Gadd45 and p53R2 than p53Arg form, p48 mRNA level has been 
quantified in these two p53 polymorphic forms.  
 
When H1299-TSp53 cell lines were shifted to 320C, p53 become active and it was 
observed that after 2 hours of p53 activation basal expression level of p48 is less in 
p53Arg containing cell line than that of p53Pro (Figure 13B). After UV stress (15 J/m2), 
p48 level is higher in presence of p53Pro form than p53Arg after 2 or 3 hours of post-
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Figure 13. Expression of p53-dependent e
ed to quantify expression of Gadd45 (A) and 
p48 (B) in H1299-based isogenic cell lines in indicated time points after UV15J/m2 
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ndogenous DNA-repair target genes in 
p53Pro and p53Arg expressing cells.  
Semi-quantitative RT-PCR was perform
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3.2.4.5 Ribonucleotide reductase gene, p53R2 
p53R2 is an important target of p53 for tumor suppression. This novel p53 target gene 
plays an important role during DNA repair by providing ribonucleotides. It is a p53 
inducible gene that contains a p53 binding sequence and encodes a subunit of the 
enzyme ribonucleotide reductase (Tanaka et al., 2000; Lozano and Elledge, 2000). 
 
At 2 hours of post-temperature shift, with or without UV irradiation (5 J/m ), expression 
of p53R2 was slightly higher in UISO stable cell line when semi-quantitative RT-PCR 
performed (Figure 14 A). Similar experiment was done on H1299 stable cells with 
higher UV dose (15 J/m ) and distinct high expression of p53R2 observed in cells 
expressing p53Pro (Figure 14 C).  
 
In order to further evaluate the expression level of p53R2 in the UISO cell line, 
immunoblot assay was carried out and p53R2 protein level was detected. Immunoblot 
assay showed a distinct high expression of p53R2 in p53Pro cells (Figure 14B) and at 2 
hours of post-temperature shift, p53R2 protein was no longer detected in p53Arg cells. 
 
Together, these data indicates that p53Pro is capable of activating endogenous p53- 
dependent DNA-repair target genes much more efficiently than p53Arg. It raises the 
possibility that UV-induced DNA damage can be repaired more efficiently by p53Pro 












Figure 14. Endogenous expression of p53R2 in
in temperature sensitiv
e PCR product was measured by 
el.Doc (A). Immunoblot assay using anti-human p53R2 antibody (B). Loading 
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PCR product was measured by Gel.Doc. Expression of p53R2 is consistently 
higher in presence of p53Pro form. Lower panel shows loading control (GAPDH). 
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3.2.5 Repair of exogenously damaged plasmids by p53 polymorphic forms 
ro, we 
.2.5.1 Host-cell reactivation assay 
ir gene expression and rate of DNA repair in 
itially the experiment was done at 24 hours of post-transfection and the results are 
Since p53Arg was less efficient in inducing DNA-repair target genes than p53P
evaluated if the DNA-repair capacity of p53Arg was also compromised compared to 
p53Pro. Two different assays were employed to investigate DNA repair efficiency. 
 
3
To assess the relation between repa
presence of p53Pro or p53Arg, host-cell reactivation assay was performed. The host cell 
reactivation assay is a method of investigating the DNA-repair capacity of cells by 
quantifying the function of repaired exogenous DNA that had been damaged before 
introduction into cells (Yang et al., 1998; Cho et al., 2002; Wani et al, 2002). pCMV-
Luc luciferase reporter plasmid was treated either with UV or gamma irradiation to 
induce damage and this DNA was transiently transfected into p53 null MEFs together 
with either p53Arg, p53Pro or control vector plasmids. Untreated pCMV-Luc was 
transfected alone as a positive control. Expression of luciferase activity, which 
corresponds to the DNA-repair rate, was monitored. Cells expressing p53Pro 
consistently demonstrated higher levels of luciferase activity compared to p53Arg-
expressing cells in experiments using both UV and γ-damaged plasmids.  
 
In
shown in figure 15A and 15B. With low dose of IR (γ25Gy), expression of pCMV-Luc 
is higher in presence of p53Pro, suggests higher DNA damage repair (Figure 15 A). 
However, no significant difference was observed when reporter plasmid was damaged 
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with γ50Gy or UV50 J/m2 and 100 J/m2. In these experiments, even cells with empty 
vector also shows DNA repair but were less than p53 expressing cells. It could be 
because of prolonged period (24 hours) allow cells to repair damaged DNA and this 
prolonged period may allow activation of DNA repair pathway independent of p53.  
 
In our next experiment, luciferase expression was measured in shorter time points to 
ll experiments were carried out with a positive (untreated pCMV-Luc) and a negative 
observe difference between p53Pro and p53Arg form. PCMV-Luc was treated with UV 
100J/m2 and 250J/m2 to induce DNA damage.  As shown in figure 15 C, p53Pro form 
shows a higher degree of DNA repair than p53Arg at 10 hours of post-transfection and 
this difference become noticeable (UV 100 J/m2: p53Pro = 25.67 and 25.92, p53Arg = 
21.95 and 22.24.    UV 250 J/m2: p53Pro = 19.21 and 18.93, p53Arg = 14.44 and 14.34) 
at 16 hours of post-transfection (Figure 15D).   
 
A
(treated pCMV-Luc) control. Another negative control experiment was included. It was 
shown that the mutant p53 (175Pro) was unable to repair damaged DNA (Figure 15 E).  
These results raise another possibility that p53Pro form may respond faster than p53Arg 
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Figure 15. Host-Cell reactivation assay to measure repair rate of exogenously-
damaged plasmid (pCMV-Luc) in presence of p53Pro and p53Arg forms in MEF.   
 
Luciferase reporter assay was done after treating pCMV-Luc with either γ-or UV-
irradiation as indicated doses at 24 hours after transfection.  
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Figure 15. Host-Cell reactivation assay continued.   
 
10 hours (C) and 16 hours (D) after transfection, expression of pCMV-Luc in MEF was 
measured. At 10 hours the difference was subtle, but it is significant at 16 hours of post-























































Figure 15. Host-Cell reactivation assay continued. 
 
A negative control experiment shows that mutant p53 (p53-aa175, dominant negative 
mutant) unable to repair UV-damaged (250 J/m2) pCMV-Luc in p53-/- MEF. The 
expression of pCMV-Luc in presence of p53-aa175 mutant is similar to the treated 
vector control, whereas wild type p53Pro shows repair of damaged pCMV-Luc. This 
rationalizes the validity of the host-cell reactivation assay.  













3.2.5.2 In vivo end-joining assay 
In order to further evaluate the DNA repair efficiency, we analysed the roles of p53Pro 
and p53Arg using the in vivo end-joining assay. DNA end-joining is part of the 
mechanism for repairing double-strand DNA breaks (Critchlow and Jackson, 1998; 
Karran, 2000). The pGL3-luciferase reporter plasmid was used to evaluate correct non-
homologous end-joining activity that precisely rejoins broken DNA ends in vivo. The 
pGL3 plasmid was completely linearized by restriction endonuclease NarI and 
transfected into the isogenic temperature sensitive cell lines. All cells expressing the 
undamaged plasmid exhibited luciferase activity at both 390C and 320C when analyzed 
18 hours post-transfection (Figure 16). However, significantly more luciferase activity 
from damaged plasmid was detected only in p53Pro expressing cells cultured at 320C 
compared to vector or p53Arg-expressing cells, indicating that the damaged plasmid 
was re-ligated much more efficiently in p53Pro-expressing cells (Figure 16). These 
differences were reproducible and consistent in several experiments. Together, these 
data suggest that p53Pro expression leads to increased DNA repair activity. 
 
3.2.6 Unscheduled DNA-synthesis in p53Pro and p53Arg expressing cells 
To further compare the ability of p53Pro and p53Arg to repair damaged DNA, 
unscheduled DNA synthesis (UDS) rate was measured using the temperature sensitive 
p53-expressing isogenic cells (H1299). In UDS, non S-phase DNA synthesis is 
measured and it is a reliable assay to check DNA repair rate in cells (Smith et al., 2000; 
Cleaver et al., 1999).   Before UV treatment, cells were kept in medium containing 
20mM hydroxyurea to eliminate cells from S-phase and to reduce background. After 
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UV treatment, cells were cultured in presence of [3H] thymidine, which are incorporated 
during unscheduled DNA synthesis. In this case, more [3H] incorporation correlates 
with increased rate of DNA repair. 
 
Cells were treated with 50J/m2 of UV, and [3H] thymidine incorporation into DNA was 
determined at 390C and at 320C after 4 hours of treatment. Incorporation of [3H] 
thymidine was almost equal in all the cell lines at 390C, indicating that p53-dependent 
repair was not taking place at this temperature (Figure 17 A). By contrast, p53-
expressing cells incorporated more [3H] thymidine at 320C after UV irradiation. 
However, p53Pro expressing cells incorporated significantly more [3H] thymidine in the 
initial experiment (Figure 17A). 
 
Similar experiments were done using two different doses of UV (25J/m2 and 50J/m2) 
and [3H] incorporation measured 6 hours after treatment.  p53Pro expressing cells 
consistently incorporated significantly more [3H] thymidine at both UV doses compared 
to p53Arg-expressing cells (Figure 17B).  
 
These data support the previous findings and p53Pro form can repair UV-induced DNA 














































































































Figure 16. In vivo end-joining assay.  
In vivo end-joining in presence of two p53 polymorphic variants at 390C (A) and at 
320C (B). The rate of end-joining is higher in presence of p53Pro than p53Arg at 320C. 
Each experiment was done in duplicates (series 1 and 2). 
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Figure 17. Unscheduled DNA-synthesis in  p53Pro or p53Arg expressing cells. 
 
H1299-based isogenic cell lines expressing either vector or temperature sensitive 
p53Pro (Pro) or p53Arg (Arg) were treated with 20mM hydroxyurea to eliminate cells 
in the S-phase, prior UV irradiation and subsequently cultured at 390C or 320C in the 
presence of [3H] thymidine. Cells were than harvested 4 hours after treatment and the 
amount of incorporated [3H] thymidine was determined by scintillation counter. High 
incorporation of [3H] refers to more DNA repair.  All experiments were performed in 
duplicates at least three times independently. Unscheduled DNA synthesis is relatively 
higher in presence of p53Pro than p53Arg. However, the difference is not statistically 
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Figure 17, continued. Unscheduled DNA synthesis inp53Pro or p53Arg expressing 
cells. 
 
After culturing cells in presence of 20mM hydroxyurea, cells were treated with UV (25J/m2 
and 50 J/m2) and culture in medium containing [3H] thymidine. Incorporation of [3H] 
measured 6 hours after treatment. At 320C, incorporation of [3H] is higher in p53Pro cells. P 






3.2.7 Removal of UV-induced cyclobutane pyrimidine dimers by p53 
polymorphic forms 
A distinct higher expression of Gadd45 in p53Pro-cells raises the possibility that these 
cells can repair UV-induced DNA damage more efficiently than p53Arg-containing 
cells, since Gadd45 is UV responsive (Zhan et al., 1996) and directly contribute to p53-
mediated NER (Smith et al., 2000). UV irradiation results in dipyrimidine 
photoproducts such as (6-4)-photoproducts and cyclobutane pyrimidine dimers (CPDs), 
the latter being predominant (Patrick, 1977). NER excision repair has been shown to be 
involved in the removal of CPDs, and defects in this process often lead to a 
predisposition to cancer (Hanawalt et al., 2003). 
 
Southwestern dot-blot analysis using an antibody directed against CPDs is one method 
to investigate the rate of removal of CPDs from DNA (Schwarz et al., 2002). Since it 
has been observed that p53Pro-expressing cells were able to repair damaged DNA 
faster, we have investigated if removal of CPDs would occur faster in p53Pro-
expressing cells. All isogenic temperature sensitive cell types were treated with UV 
irradiation and genomic DNA was collected at various time points, and equal amounts 
of genomic DNA was used to detect CPDs (Figure 18E).  
 
In first experiment, cells were treated with UV50J/m2 and genomic DNA was extracted 
at seven different time points (30 minutes, 1 hour, 3 hours, 24 hours, 48 hours, 96 hours 
and 102s hour). Untreated cells did not contain any CPDs either at 390C or 320C (Figure 
18A). UV treatment resulted in formation of CPDs immediately (within 5 minutes). 
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From this experiments it is shown that CPD starts to disappear in presence of both 
p53Pro and p53Arg form in 1 to 3 hours and within 48 hours all the cells have removed 
their CPDs (Figure 18A).  
 
A second experiment was done using 1μg of genomic DNA under similar condition 
except the DNA collection time points were shorter than the previous one. After UV 
treatment (50J/m2), DNA was extracted at 0, 1, 1and half, 2, 3 and 4 hours time points. 
Results show that CPD starts to disappear faster in presence of p53Pro form than that of 
p53Arg and this difference of CPD disappearance is distinct between 2 to 4 hours 
(Figure 18 B).  
In the third experiment, the previous conditions were kept but with 0.5μg of DNA. We 
reduced the amount of genomic DNA in order to observe a clearer difference, if any. 
The result observed in second experiment is consistent with the previous two 
experiments. Within one and half hour, CPD started to disappear in presence of p53Pro 
form whereas in p53Arg form, this event observed after 3 hours. The difference in 
gradual disappearance of CPD in p53Pro form is faster than p53Arg form (Figure 18C).  
 
The result from these series of experiment was consistent and the data indicates that 
although both p53Pro and p53Arg are capable of CPD removal, the process is much 




















Figure 18. CPDs are removed rapidly in p53Pro-expressing cells compared to 
p53Arg-expressing cells. 
 
A). H1299-based isogenic cell lines expressing either vector or temperature sensitive 
p53Pro or p53Arg were treated with UV irradiated (50J/m2) for the indicated time 
periods at the indicated temperatures. Control cells were left untreated. After extracting 
genomic DNA, South-Western blotting was performed to measure the removal rate of 
CPD by different p53 polymorphic forms. Data show that the CPD removal rate is 




























Figure 18, continued 
B).  Difference in CPD removal rate by two p53 polymorphs can be observed within 2 











































































C). The difference of CPD removal by p53 polymorphs is in shorter time point.  










Figure 18, continued 
 
 
E). Equal amount (500 ng) of genomic DNA was used to analyze removal rate of CPD 





























3.2.8 Formation of micronuclei in p53Pro or p53Arg expressing cells 
Micronuclei are broken, short fragments of chromosome and due to lack of centromere, 
they cannot attach to the spindle fibers. During karyokinesis, these broken chromosome 
fragments form micronuclei. So, micronuclei formation is related to chromosomal 
aberration and has been used widely to measure chromosome damage, and is 
recognized as a consequence of genome instability (Matsuoka et al., 1992; Stopper et 
al., 1997; Fenech, 2002). Because of the specificity, micronuclei assay is also used to 
monitor mutagenic property of chemical wastes (Kyoko and Makoto, 2003). Since 
p53Pro-expressing cells were able to repair damaged DNA more efficiently than 
p53Arg-expressing cells, we next evaluated if micronuclei formation would also be 
affected by p53Pro expression. Cells were treated with gamma irradiation and cultured 
for 24 hours to allow repair of damaged DNA in the presence of cytochalasin B, which 
prevents cytokinesis at telophase, and the number of binucleated cells with micronuclei 
were counted. Untreated cells did not contain any micronuclei both at 320C (Figure 
19A, top row) and at 390C (data not shown). Irradiation of cells led to micronuclei 
formation to equal extents at 390C in cells expressing either vector or the p53 
polymorphic variants, indicating that DNA damage has occurred and p53 was unable to 
correct the defect as it is at the inactive form at this temperature. Both at 320C and 390C, 
vector-expressing cells had the highest number of micronuclei (Figure 19A, middle and 
bottom row-right lane) and similar trend was observed in p53Pro- and p53Arg- 
expressing cells (Figure 19A, bottom row). At 320C, when both p53Pro and p53Arg 
form are in active conformation, micronuclei formation is significantly reduced in these 
cells. However, the number of cells containing micronuclei was always consistently 
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lower in p53Pro-expressing cells compared to p53Arg-expressing cells (p53Pro vs. 
p53Arg: 15.5% vs. 23.0%) (Figure 19A and 19B). Similar results were obtained with 
different doses of γ-irradiation (data not shown) and these differences were consistently 
reproducible. Together, these data suggest that p53Pro-expressing cells are more 
efficient in repairing chromosomal damage and prevent micronuclei formation in cells. 
p53Arg-expressing cells are also capable of removing micronuclei, however, our 
vigilant observation suggests that these cells are not as efficient as p53Pro cells in 

































Figure 19.  Comparison of micronuclei formation in H1299 cells expressing either 
p53Pro or p53Arg.  
 
A). After γ-irradiation (30Gy), cells were stained with acrydine orange and visualized 
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Figure 19, continued. 
 
B). Percentage of micronuclei in presence of p53Pro, p53Arg and vector. Total of 500 
bi-nucleated cells were counted for analysis. In untreated cells micronucleus was not 













3.3 p53 polymorphism and melanin synthesis 
From the data gathered, the distribution of p53 polymorphs shows a correlation between 
p53 polymorphism and latitude and this shows distinct differences between major 
ethnic groups (Beckman et al., 1994; Sjalander et al., 1996); populations living near the 
equator have a high frequency of p53Pro allele and as we move towards the North Pole, 
the p53Arg allele ratio increases. Expression pattern of p53 allele in heterozygotes 
(p53Pro/P53Arg) showed that this follows the normal distribution of p53 polymorphs in 
different geographical regions. Frequency of p53Pro is higher in the Equator and the 
heterozygotes in this population preferentially express p53Pro allele, even though the 
p53Arg is predominant in this group of population (Chinese). In the Northern 
Hemisphere (Poland), the p53 heterozygotes express p53Arg allele preferentially; again 
it follows the natural distribution of p53 polymorphs in this region.  
 
Based on these data together with other findings, we have proposed that the p53 codon 
72 polymorphism has an association with skin colour. It has been observed that 
population with fair skin predominantly expresses the p53Arg allele while those with 
darker tan have the p53Pro allele. Furthermore, in the equatorial region, which has the 
most exposure to sunlight and solar UV radiation, the p53Pro allele is predominant.  
 
Since p53 can activate melanin synthesis genes (Nylander et al., 2000; Kichina et al., 
1996), it raises the possibility that these two p53 polymorphic variants may have a 
differential effect in regulating the expression of melanin producing genes.  
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Tyrosinase related protein-1 (TRP-1) and tyrosinase are key enzymes in synthesis of 
melanin and both of these genes can be activated by p53 (Nylander et al., 2000; Kichina 
et al., 1996). Our data shows that the p53Pro allele may have a more significant role in 
producing melanin by up regulating these genes than p53Arg to protect the skin in the 
equator.  
 
3.3.1 Expression of TRP-1 and Tyrosinase promoters in two p53 polymorphic 
forms 
In luciferase reporter assays, tyrosinase related protein-1 (TRP-1) and tyrosinase 
promoter expression was observed to be higher in p53Pro than p53Arg expressing cells 
(Figure 20A). p53 null human cell line, UISO was co-transfected with either p53Pro or 
p53Arg form along with either TRP-1 or Tyrosinase promoter driven luciferase reporter 
vector pGL3 (Promega).  β-gal expressing vector was used to normalize the transfection 
efficiency.   
 
In the first experiment, cells were analyzed for luciferase expression at 24 hours of post-
transfection. Expression of Tyrosinase promoter was 52 and 60.6 in p53Pro, 42.9 and 
39.6 in p53Arg, and 38 and 33.1 in vector expressing cells (Figure 20 A, left). For TRP-
1 promoter, expression was highest in presence of p53Pro (47.9 and 42.7) than p53Arg 
(36.6 and 38.4) and vector (38.2 and 38.5) (Figure 20 A, right).  
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In the next experiment, reporter assays were done in two different time point to observe 
the difference in promoter expression in p53Pro and p53Arg form. Expression of the 
tyrosinase promoter was consistently higher in cells with p53Pro form than that of 
p53Arg in both 20 hours and 40 hours of post-transfection (Figure 20 B-C, left). In case 
of TRP-1 promoter expression, difference between p53Pro and p53Arg containing cells 
was distinct. However, after 40 hours, both p53Pro and p53Arg showed equal 
expression of TRP-1 (Figure 20 B-C, right). 
 
To support these observation, TRP-1 mRNA was compared between p53Pro and 
p53Arg expressing cells and the data showed that expression of TRP-1 was highest in 
p53Pro cells at 3 hours of post-irradiation (Figure 24).  
 
These reporter assays indicated that p53 codon 72 polymorphism may affect the 
expression of melanin producing genes and p53Pro may produce more melanin than 
p53Arg. Similar experiments have been done under different conditions to observe the 
expression of TRP-1 –Luc or tyrosinase – Luc promoters.  In all cases, expression of 
these promoters was relatively higher in presence of p53Pro than p53Arg form (data not 
shown). However, due to lack of sufficient replications, we could not perform statistical 
analysis. Melanin quantification was done subsequently for better understanding of this 




3.3.2 Synthesis of melanin in presence of two p53 polymorphic forms 
Next, a series of experiment with p53 null melanoma cell line UISO were done to assess 
the effect of p53 polymorphs on melanin synthesis. The temperature sensitive p53-
UISO stable cell line was either treated or untreated and melanin content was measured. 
Results showed that melanin content was significantly higher in both treated and 































































































Figure 20. Reporter assay shows activation of tyrosinase and TRP-1 promoter in 
presence of p53Pro or p53Arg. 
  
 
Expression of tyrosinase (left) and TRP-1 (right) promoters in UISO cell line after 24 















































Figure 20, reporter assay continued.  
Expression of Tyrosinase and TRP-1 promoter in UISO cell lines in presence of p53Arg 
or p53Pro, 20 hours (B) and 40 hours (C) of transfection.  
Each experiment was done in duplicates (series 1 and 2). 


































































































































































































Figure 21. In vitro assay to quantify melanin . 
 
Amount of melanin measured in UISO stable cell line that express either p53Pro or 
p53Arg form with or without UV 20J/m2. P value indicates that the difference is 
significant (one-tailed student’s t-test). 
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Based on these data, the next experiment was aimed at assessing the melanin contents in 
p53Pro and p53Arg expressing cells after treating the cells repeatedly with UV.  
 
When the UISO-TSp53 cell lines were repeatedly treated with UV (5J/m2in every 24 
hours for 8 days) p53Pro expressing cells produced more melanin than p53Arg cells. 
However, the production of melanin went down gradually after repeated UV treatment 
(Figure 22). This may be because of excess stress, and cells undergo apoptosis in a p53 
dependent manner. Also, it is reported that overexpression of p53 can down regulate 
TRP-1 and Tyrosinsae genes (Kichina et al., 1996). This may due to excess stress leads 
cells to switch on other mechanism rather than producing melanin to absorb UV.  
 
This supports our hypothesis that p53 polymorphism is naturally selected for better 
survival and ecological adaptation of the individual.  Based on these melanin producing 
capabilities, we postulated that p53 polymorphism is a natural phenomenon for the 
ecological adaptation of the individual.  
 
3.3.3 Synthesis of melanin in presence of endogenous p53 polymorphic forms 
Human melanoma cell lines with endogenous wild type p53 of either Pro or Arg 
genotype (from Memorial Sloan-Kettering Institute, USA) were used to confirm the 
previous findings. In these cell lines, the amount of melanin was observed to be higher 
in p53Pro than p53Arg genotype (Figure 23B). When the cells were grown in culture, 
this difference was clearly visible (Figure 23A). 
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For measuring melanin, 2X105 cells were lysed with 1N NaOH. Equal amount of total 
cell lysate was used to measure the concentration of melanin. SK-Mel 19 and SK-Mel 
85 harbouring wild type p53Pro form, and SK-Mel 5 and SK-Mel 103 with wild type 
p53Arg form were used. Due to low concentration of SK-Mel 103 lysate, melanin 
concentration of this cell line could not be determined. These cell lines were grown in 
tissue culture petridish and treated with UVC 5 J/m2 repeatedly for three times at 24 


















 Figure 22. Melanin content was measured after treating UISO cells stably 
transfected with either p53Pro or p53Arg .  
 
After first treatment (5J/m2), melanin content was highest in all cells and repeated UV 
treatment results gradual decrease in melanin synthesis. However p53Pro always 
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Figure 23. Melanin in cells with endogenous p53. 
 
A). SK-Mel cell lines were grown in tissue culture dish and observed pigmentation. 








    390C                                   320C  
    Untreated         Untreated       UV 5J-1H        UV 5J-3 H  






















 (P= p53Pro, R=p53Arg, V=Vector) 
 
 
Figure 24. Expression of TRP-1 in temperature sensitive p53-UISO stable cell line. 
 
















3.4 p53 mutations and response to chemotherapeutic drugs 
Since p53 polymorphism may have a differential effect on apoptosis, inducing cell 
cycle arrest and DNA repair, drugs that target p53 may have varying effect on 
individuals with different p53 genotypes. In some cancers, the presence of specific type 
of p53 mutation may be predictive of the tumor response to treatment and patient 
survival. To investigate this, six hot-spot mutant p53 of both p53Pro and p53Arg forms 
were made in pCDNA3. Human lung cancer cell line H1299 (ATCC), which is p53 
null, was stably transfected with different p53 mutants. Stable cell lines with pCDNA3-
p53 mutants have been used to study their response to different cancer therapeutic 
drugs.  
 
3.4.1 Generation of mutant p53 expressing isogenic cell lines.  
Six p53 hotspot mutations (i.e., R175H, G245S, R248W, R249S, R273H, and R282W), 
either in the p53Arg or p53Pro forms were generated by site-directed mutagenesis, in 
the pCDNA3 vector. All constructs were sequence verified (Figure 25). Cells 
expressing the various p53 mutants were tested for expression of the mutant p53 by 
reverse transcription-PCR analysis and immunoblotting and were found to express 
equal amounts of p53 (Figure 26) and hence were used for evaluation of their response 
to various chemotherapeutic drugs.  
 
3.4.2 Effect of p53 mutation and polymorphic status in H1299 cells to anticancer 
drugs 
All the H1299-p53 mutants cell lines were used to observe their response to various 
anticancer drugs: cisplatin, etoposide, gemcitabine, vinblastine, taxol, and doxorubicin. 
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Cellular response to drugs was determined by the standard MTT assay, which 
determines the metabolic viability, due either to the cytostatic and cytotoxic effects of 
the drugs (Hayon et al., 2003). Taxol treatment resulted in minor resistance of cells 
expressing the p53-249 mutant, but there were no significant differences between the 
p53Arg and p53Pro forms (data not shown). 
 
3.4.3 p53 polymorphism affects the response of H1299 cells expressing 249-p53 
mutant to doxorubicin 
In case of doxorubicin, there was no significant difference between p53 mutants except 
p53-249 mutant. The 249-p53Arg-expressing cells were found to be more resistant than 
the 249-p53Pro and vector-expressing cells over a range of drug concentrations 
(Appendix I). Thus it was analyzed if the resistance conferred by 249-p53Arg 
expression was due to reduced apoptosis, by staining with Annexin V and propidium 
iodide. 249-p53Arg-expressing cells were found to undergo less apoptosis compared 
with vector expressing cells or 249-p53Pro-expressing cells at various concentrations of 
doxorubicin treatment (Appendix II), suggesting that the resistance conferred by 249-




























Figure 25. Sequence analysis of  wild type p53 and SDM-generated p53 mutants. 
 
Wild type p53Pro and p53Arg (top). p53Pro is represented by CCC nucleotide sequence and 
p53Arg as CGC.  
Sequence analysis of the various p53 hotspot mutants (bottom). Both wild-type and mutant 
sequences are represented and underlined, as follows: 175 (wild-type versus mutation: CGC 
versus CAC), 245 (GGC versus AGC), 248 (CGG versus TGG), 249 (AGG versus AGT), 




Figure 26.  
Western blot analysis of H1299 cells stably expressing p53 hotspot mutants. Whole cell 


















Chapter 4. Discussion 
4.1 Distribution and expression of p53 codon 72 polymorphism 
There are 33 single nucleotide polymorphisms (SNPs) so far reported in human p53 
gene, only six of them are in the exons. Among these six SNPs, only two SNPs alter 
amino acid sequences of its product, proline to serine at residue 47 (Felley-Bosco et al., 
1993) and arginine to proline at residue 72 (Matlashewski et al., 1987). p53 codon 47 
polymorphism changes an evolutionary conserved proline residue to serine. p53 codon 
47 proline is the most common polymorphic forms and p53 codon 47 serine is very rare 
(less than 5%) polymorphic variant in African Americans and absent in Caucasians (Li 
et al., 2005; Felley-Bosco et al., 1993).  In this study, we have analyzed the functional 
differences of different p53 codon 72 polymorphic forms which is the most common 
polymorphism and is maintained at different allelic frequencies across the population of 
the world (Sjalandar et al., 1995).  
 
The significance of p53 polymorphism in the development of cancer is still unknown. 
Several studies have been done on the distribution of p53 codon 72 polymorphism in 
different populations. In this study, we analyzed the association of p53 codon 72 
polymorphism between different ethnic populations in Singapore. In addition, we also 
attempt to correlate the prevalence of a particular p53 polymorphic form in breast 
cancer population. This study shows that Chinese population has a relatively large 
number of p53Arg/p53Arg similar to the Caucasian population. Indian population on 
the other hand, contains a large number of p53Pro/p53Pro homozygotes with the Malay 
population in between the Chinese and the Indians. The distribution suggests that the 
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p53 codon 72 polymorphism has a particular tendency to associate with specific race or 
ethnic groups.  
 
4.1.1 Expression of p53 allele in healthy heterozygotes 
The initial study showed that the Chinese population has predominantly p53Arg allele 
and a large number of them are heterozygotes (p53Pro/p53Arg). Which allele of a gene 
will be expressed is still a matter of debate; we were interested to investigate the 
expressing allele of p53 in the heterozygotes; in an attempt to investigate if there is any 
preferential expression of a particular allele. Interestingly, we found that all the Chinese 
germline healthy heterozygotes express either the p53pro allele alone, or express both 
the p53pro and p53arg alleles, but none of them expressed the p53Arg allele. This 
suggests that there may be a biological significance on the expression of p53 alleles in 
heterozygotes in population. This also suggests that this p53Pro or p53Arg alleles may 
be selected naturally and our data along with existing data (Beckman et al., 1994) 
suggest that p53Pro is predominant near the equator whereas p53Arg is higher near the 
North Pole. So, even though the p53Arg is higher in Chinese population, the 
heterozygotes tend to express p53Pro and not p53Arg due to the selection pressure. To 
support this finding, similar studies need to be done in different populations such as: 
Australian and South American populations where, according to their ethnic origin, 
p53Arg is supposed to be dominant (Beckman et al., 1994; Sjalander et al., 1996). 
Expression status of p53 codon 72 heterozygotes may tell whether there is any selection 
pressure for the expression of this particular p53 allele.  
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4.1.2 Expression of p53 allele in breast cancer patients 
Expression analysis of p53 heterozygotes in Chinese breast cancer patients was done in 
a similar way as healthy heterozygotes. Interestingly, most of the germline 
heterozygotes either expressed p53Arg allele or they tend to express p53Arg alleles 
more than p53Pro. The contrasting result with that of healthy heterozygotes suggest that 
p53Pro allele could be preferentially silenced or down regulated in breast cancer, 
accompanied by over expression of p53Arg allele. This raises the possibility that 
expression of p53Arg allele in heterozygotes may be associated with breast cancer 
susceptibility.  Because there is a distinct absence of p53Arg expression in healthy 
heterozygotes, it seems that p53Pro is silenced in breast cancer or somehow down 
regulated and causes over expression of p53Arg allele. We exclude the possibility of 
LOH (loss of heterozygosity) because the genomic DNA sequence showed that our 
selected heterozygote samples carry both p53Pro and p53Arg alleles. From our 
preliminary study on DNA methylation assay, we also exclude the possibility of 
hypermethylation of the p53Pro allele.  
 
The present study is based on Singaporean Chinese breast cancer patients. However, to 
understand the association of p53 polymorphism with breast cancer susceptibility, it 
will be interesting to carry on similar investigations in Indian as well as European breast 
cancer population. Also, the size of the study population must be substantial enough to 
represent the population statically.   
   
 
 114
4.1.3 Association of p53Arg allele in breast cancer susceptibility 
The unequal and selective expression of p53 alleles in heterozygotes raises the 
possibility that p53Pro allele in breast cancer may be down regulated and the 
compensated expression of p53Arg may lead to increase cancer susceptibility.  To 
investigate if there is an allelic switch in the expression of the different p53 codon 72 
alleles during cancer development, expression of p53 alleles in healthy heterozygote 
tissues and cancer tissues were compared. The results show that histologically normal 
adjacent tissues from heterozygote cancer patients preferentially expressed p53Arg 
allele. This is in contrast to normal breast tissues from healthy heterozygote donors, 
who primarily express the p53Pro allele, similar to the observations with peripheral 
blood of the Chinese population. This suggests that p53Arg allele is expressed in these 
cancer patients. However, we cannot exclude the possibility that p53 is imprinted, 
resulting in silencing of the p53Arg allele in healthy Chinese individuals, through 
mechanisms that require further investigation. It will be interesting to investigate if 
there is endogenous micro RNA which can silence one of the alleles in normal as well 
as cancer tissues.  
 
This raises the possibility that the p53Arg allele may not be functionally involved and 
could be a weaker variant to prevent carcinogenesis. To understand this, the mutational 





4.1.4 Mutation of p53 in breast cancer 
Analysis of p53 mutation in Chinese breast cancer patients showed that 44% of the 
individuals carry a mutation in the p53 gene. This supports the previous findings that 
p53 is mutated in 50% of all human cancers (Matlashewski et al., 1987, Hainaut et al., 
1998). However, the interesting finding is that most of the p53Arg form (about 67%), 
which is considered reactivated in cancer, do not carry any mutation. Whereas 56% of 
the p53Pro form carry mutation and these mutations are mostly in the DNA binding 
domain (90%, 21 out of 23 mutation). Moreover in mutant p53Arg form only 37% are 
mutated in the DNA binding domain.  Of the mutations found outside the DNA-binding 
domain, about 25% of them were on codon 80 (which is in the proline-rich region). The 
mutation in codon 80 results in the substitution of a proline to serine residue further 
reducing the number of proline in the proline-rich domain. The significance of the 
proline rich domain has been reported and it is involved in mediating apoptosis (Walker 
et al., 1996). Since wild type p53Arg lack of a proline residue at cocon 72, further 
alteration in this region may greatly decrease p53’s pro-apoptotic property. This again 
suggests that p53Arg form may be associated with cancer. Because of this, even though 
67% of the p53Arg forms are wild type in breast cancer, they cannot prevent 
carcinogenesis. On the other hand, p53Pro requires a strong mutation to inhibit p53’s 
function and lead to cellular transformation. Again, it raises the possibility that the 




Frequency of codon 248 was found to be significantly higher in this breast cancer 
population. This is one of the six hotspots that are frequently mutated in cancer. Since 
43% of total mutations are found in this hotspot, it will be interesting to characterize 
and study the response of this mutant to chemotherapeutic drugs and the findings could 
have clinical significance. 
 
4.1.5. Wild-type p53Arg form may predispose to breast cancer 
About 67% of the samples with p53Arg form were wild type in study population (breast 
cancer). Among the mutant p53Arg, about 62% are considered recessive mutations, that 
carry a point mutation outside of the DNA binding domain. The presence of a large 
number of wild type p53Arg form along with recessive mutants in breast cancer 
samples suggest that this particular allele may be a cancer susceptible p53 allelic 
variant. By contrast, 55% of p53Pro allele was found mutated and most of the 
mutations are at the DNA binding domain, which are considered dominant mutations. 
This suggests that there is a strong genetic pressure to selectively mutate the p53 gene at 
the DNA-binding domain to abrogate the DNA-binding function of the p53Pro allele, 
as compared with the p53Arg allele. Thus we hypothesize that majority of p53 in breast 
cancer which do not contain a mutation is the p53Arg polymorphic variant. Although 
the p53Arg has been shown to induce apoptosis better than the p53Pro form (Dumont et 
al., 2003), our preliminary study showed that this may be cell type or stress specific. 
Different type of cell lines with p53Pro or p53Arg may respond differently. 
Furthermore, apoptosis is not the only function of p53 to prevent tumourigenesis, 
p53Arg form may be weaker to induce other functions compared with p53Pro form. 
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Other studies that have detected a considerable link between p53Arg allele and an 
increased risk of breast cancer in different populations also support the above findings 
(Ohayon et al., 2005; Buyru et al., 2003; Langerod et al., 2002).  Thus, the above data 
suggest that the p53Arg individuals may be more susceptible to predispose to breast 
cancer than their p53Pro counterparts.  
 
However, the biological role of p53 codon 72 polymorphism in cancer susceptibility 
deserves further investigation. With the various possible selection biases inherent in this 
type of association studies, replications of studies in other ethnically and geographically 
different populations can help to better understand our obtained results.  
 
4.1.6 Expression of p53 codon 72 allele can be used as a predictive factor in 
cancer development 
The data presented here show that there may be a selection pressure against the 
expression of the p53 p53Arg allele in the healthy Asian germ line p53Arg/p53Pro 
heterozygotes and it also shows an association between the expression of the p53Arg 
allele and susceptibility to breast cancer development.  
 
Thus, we propose that the expression status of the p53 polymorphs, rather than the 
conventionally analyzed genomic status, be used as one predictive factor for the 
predisposition to cancers.  
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This association study that defines susceptibility of p53Arg form to breast cancer may 
provide important insights into the pathogenesis of breast cancer, but should be treated 
with caution until independent replicates are produced in well representative cohorts.  
 
4.2 Functional significance of p53 polymorphism 
To understand the significance of p53 polymorphism in cancer, we have analyzed the 
functional difference of p53Pro and p53Arg forms. Dumont et al., (2003) reported that 
p53Arg form induces seven fold-increased apoptosis compared with the p53Pro form. 
However, this observation is still controversial. In our hands, we have yet to see such a 
property of p53Arg, though we did observe that the apoptotic property of p53Arg form 
is slightly higher than p53Pro (but not seven times). We have concluded that this 
discrepancy could be cell type related as p53 responds differently in different cell types. 
Apoptosis is influenced by cell type, cellular environment and other genetic alterations 
sustained by the cell (Ryan et al., 2001; Vousden, 2000). Besides inducing apoptosis, 
transactivation of DNA repair genes is one of the important known functions of p53. 
Since p53 can protect against cellular transformation by repairing damaged DNA, we 
have investigated whether DNA repair efficiency by these two p53 polymorphic 
variants are different in order to explain the functional significance of p53 codon 72 
polymorphism in carcinogenesis. 
 
4.2.1 p53 polymorphism and DNA Repair 
Several experiments have been done to evaluate the DNA repair efficiency by these two 
p53 polymorphs. The first is based on the study on the expression of repair gene 
promoters by p53. The results indicate that the p53Pro form activated repair gene 
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promoter faster than p53Arg. A limitation of our luciferase reporter assay is the lack of 
significant numbers of replication for each experimental unit. However, these 
preliminary studies led us to analyze the expression of the DNA repair genes that are 
upregulated by p53 as well as repair of damaged DNA by these two p53 polymorphic 
variants. . 
 
Expression levels of major DNA repair genes were measured in cell lines that contain 
either p53Pro or p53Arg forms using semi-quantitative RT-PCR. Consistently, it was 
observed that expression of p48, Gadd45 and p53R2 is always higher in p53Pro 
expressing cells. As Gadd54 expression can affect G1 arrest and nucleotide excision 
repair of DNA (Smith et al, 1994; Zhan et al, 1994), increased expression of this gene 
may cause rapid cell cycle arrest and nucleotide excision repair in p53Pro form. 
Similarly, higher expression of p53R2 can induce the p53 checkpoint for repair of 
damaged DNA (Byun et al, 2002). Since the expression of both genes is relatively 
higher in presence of p53Pro, it suggests that p53Pro allele is more efficient in DNA 
repair and expression of p53Arg allele in presence of xenotoxic stress may be 
disadvantageous to the individual. 
 
We have observed that the expression patterns of Gadd45, p48 and p53R2 are not 
similar. This may be so as the expression of p53 target genes is variable depending on 
the experimental system used and depends on their functional preference (Godefroy et 
al., 2004; Murphy et al., 2002; Sionov and Haupt, 1999). Moreover, it is similar to 
differences between bax and p21, the latter being stronger target for p53 than bax. The 
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molecular basis for the different target efficiencies is not clear at the moment, but do 
exist (Canman et al., 1998; Yu et al., 1999) 
 
4.2.2 p53Arg allele is less efficient to repair damaged DNA 
The weaker property of p53Arg form in activation of repair genes raised the possibility 
that this particular allele is associated with DNA damage-related cancer. Preferential 
expression of p53Pro allele in Chinese healthy p53Arg/p53Pro heterozygote at the RNA 
level and preferential expression of p53Arg allele in most heterozygote breast cancer 
patients suggest that p53Arg expression correlates with breast cancer development. 
Moreover, it was also demonstrated that there is a significant positive association 
between p53Arg and susceptibility to sunburn, which is a known risk factor, leading to 
a significant association between p53Arg homozygosity and nonmelanoma skin cancer 
in renal transplant recipients (McGregor et al., 2002). p53Arg consistently showed its 
weaker property in DNA repair when host reactivation , in vivo end-ligation or 
unscheduled DNA synthesis examined. Similarly, p53Arg-expressing cells are less able 
to remove micronuclei, which is related to chromosomal aberration and a reliable assay 
to measure the extent of DNA damage. 
 
4.2.3 Weaker property of p53Arg in DNA repair may cause cellular 
transformation 
The investigation on DNA repair by p53 polymorphic variants suggests that p53Pro is 
more efficient in DNA repair than p53Arg form. However, p53Arg allele also showed 
to transactivate DNA repair genes and repair damaged DNA, but slightly weaker than 
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p53Pro form. So, the reduced ability of p53Arg form to repair damaged DNA may 
allow cellular transformation even though p53Arg is wild type. This supports previous 
findings where it was found that 67% of individual with p53Arg do not have any 
mutation in the p53 gene. This also supports another study where it has been found that 
about 72% of Caucasian p53Arg breast cancer patients do not have any mutation in the 
p53 gene (Langerod et al., 2002).  
 
4.2.4 Subtle difference between two polymorphs may affect p53’s downstream 
function significantly   
Activation of DNA repair genes in presence of p53Pro also supports the findings of 
Thomas et al. (1999) where they have suggested that p53Pro and p53Arg have 
differential abilities to transactivate p53 target genes. This subtle difference between 
p53Pro and p53Arg form to induce DNA repair was consistent in all of the experimental 
methods used. Since p53 lies at the heart of the stress response of a cell, this subtle 
difference may cause substantial difference in the p53’s downstream function.    
 
 In this respect, it has been shown that the polymorphism in the Mdm2 promoter 
(SNP309) was involved in cancer susceptibility (Bond et al., 2004). A single nucleotide 
polymorphism at position 309 in the first intron of the mdm2 gene causes increased 
affinity for the ubiquitous transcription factor SP1 and in cells homozygous for SNP309 
(G/G) the p53 pathway is compromised (Bond et al., 2004). 
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Therefore, it can be suggested that a subtle difference in function of this cellular 
gatekeeper (p53) can contribute to cellular transformation. High apoptotic property of 
p53Arg for (Dumont et al., 2003) and higher DNA repair ability of p53Pro form (this 
study) suggest that there is a natural balance in the function of p53. Due to reduced 
ability of DNA repair, p53Arg cells may undergo apoptosis faster than p53Pro cells 
upon stress. On the contrary, after stress, p53Pro form repair damaged DNA faster than 
p53Arg as their ability to induce apoptosis is less than p53Arg.  
 
The physiological differences in the functions of the two different p53 polymorphs are 
not well known. More systematic study is necessary to understand their functional 
property. Since p53 performs its functions by upregulating the transcription of its target 
genes (el-Deiry et al., 1992; Vogelstein and Kinzler, 1992), chromatin immuno-
precipitation (CHIP) assay can be done to observe the binding efficiency of these two 
p53 polymorphic variants to the DNA repair gene promoters.  
   
A number of cancer drugs target p53 mediated pathway that induces cell cycle arrest or 
apoptosis of the cancer cells (McGill and Fisher, 1999; Sellers and Fisher, 1999; Bunz 
et al., 1999). Recent clinical studies also suggested that this p53 polymorphism can be a 
predictor of tamoxifen response (Wegman et al., 2006) and anthracycline-based 
treatment (Xu et al., 2005). Thus, if the above observation is reproducible and 
consistent, p53 polymorphism can be used as a genetic marker to treat patients with 
chemotherapeutic drugs.  
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4.2.5 Role of p53 codon 72 polymorphism in preventing skin cancer 
p53 codon 72 polymorphism has been implicated in skin cancer and several studies 
suggest that p53Arg form is associated with increased skin cancer risk (de Oliveira et 
al., 2004; Chen et al., 2003). Weaker DNA repair property of p53Arg may be 
responsible for this increased risk of cancer, as it has been observed in breast cancer. 
However, before the DNA becomes affected by UV, skin cells produce melanin to 
absorb UV and minimize DNA damage (McGregor and Hawk, 1999; Kobayashi et al., 
1993). Interestingly, in this study it was found that p53 polymorphism has an 
association with skin complexion which is similar to the findings of Beckman et al. 
(1994).  In this study, we have analyzed the distribution of the p53 polymorphic variants 
in stable populations with different geographical origins and have settled close to the 
Equator, i.e., the Chinese, Indians and Malays in the city state of Singapore. Our data 
indicate that the Indian population with a darker tan has predominantly the p53Pro 
allele. The Chinese population with the fair complexion has a large proportion of 
p53Arg allele whereas the Malay population which is mildly tanned have a mixture of 
both p53pro and p53Arg alleles. As it appears that there is a preferential expression of 
the p53Pro allele in the equatorial region, we investigated if this expression profile is an 
adaptive response to sunlight (UV light).   
 
4.3 Effect of p53 polymorphism in melanin synthesis 
We have investigated the expression of melanin synthesizing genes as well as melanin 
content in presence of p53Arg and p53Pro forms. The data showed that genes involved 
in melanin synthesis, i.e., tyrosinase and tyrosinase related protein-1 (TRP-1), are 
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differentially regulated by the p53 polymorphs. It has been observed that p53Pro can 
transactivate both tyrosinase and TRP-1 promoter better than p53Arg. However, this 
result is based on our preliminary study and no statistical analysis was done. 
Nevertheless, this preliminary observation suggests a tendency of upregulating 
tyrosinase and TRP-1 gene promoters by p53Pro form. These two enzymes are the key 
enzymes in melanin synthesis in mammalian cells (Khlgatian et al., 2002; Urabe et al., 
1993). Regulation of tyrosinase activity is complex but appears to occur in part at the 
level of gene transcription and both of these genes can be transactivated by p53.  
 
To confirm higher expression of tyrosinase and TRP-1 promoter in presence of p53Pro 
for, we have quantified the amount of melanin produced in the stable cell lines that 
express either p53Pro or p53Arg. Results showed that melanin content was always 
higher in p53Pro expressing cell lines which suggests that p53Pro form may be more 
efficient in up regulating melanin synthesis pathway to protect the skin from UV-
induced DNA damage. Similarly, when the amount of melanin was quantified in cells 
that contain endogenous p53, the difference of melanin content was significantly higher 
in cells with p53Pro form.   
 
These observations suggest that p53Pro individuals may have darker skin complexion 
than p53Arg individual because of more melanin produced by p53Pro and this helps the 
p53Pro individual to adapt better than p53Arg individual in places where there are 
plenty of sunlight or solar UV.  
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This hypothesis is based on expression of TRP-1 and the amount of melanin found in 
p53Pro or p53Arg expressing cells. High expression of tyrosinase and TRP-1 correlates 
with increased synthesis of melanin in mammalian cell (Yoneta et al., 2005; Nishioka et 
al., 1999; Luo et al., 1994; Hara et al., 1994; Hearing et al., 1989). However, it should 
be noted that melanin synthesis in mammalian cell is a complex process. Though 
tyrosinase and TRP-1 are the key enzymes in this process, several other genes and 
factors influence and control melanin synthesis in human cells (Urabe et al., 1993) and 
there are several genes that inhibit tyrosinase and TRP-1 to control their expression 
(Tatzel et al., 2005).  In this regard, LAMP gene family and Calnexin/p90 have been 
found to play an important role in melanogenesis (Ota et al., 1998; Salopek and 
Jimbow, 1996; Hara et al., 1994). Expression study of these genes in presence of 
p53Pro or p53Arg may further clarify our findings. However, it should also be noted 
that p53 is likely not the main regulator of the melanin synthesis genes, and may be just 
another contributing factor. Thus, the results suggest a tendency and need to be further 
explored in other detailed studies. 
 
4.3.1 p53Pro form may protect individual from UV-induced DNA damage 
The clinical nature of skin color distribution suggests an association with environmental 
factors varying with latitude, UV and temperature. Selection favours dark skin (high 
melanin pigmentation) in areas of high Ultraviolet (UV) radiation from sunlight. 
Because highly pigmented skin provides partial protection to solar UV, the selection 
would favour dark skins in high UV areas (Relethford, 1997; Barsh, 2003). In this 
respect, skin cancer occurs at high frequencies and early ages among Albinos in Nigeria 
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(Okoro, 1975). There are also some data suggesting that depigmentation in high UV 
areas results in earlier death (Lookingbill et al., 1995; Kromberg et al., 1989; Luande et 
al., 1985), producing possible selection for dark skin in an area of high UV insulation or 
sunlight.  
 
The distribution of p53 codon 72 polymorphism suggests that p53Pro form is associated 
with dark skin complexion whereas p53Arg is associated with fair skin (Beckman et al., 
1994; this study).  Our study also shows that p53Pro produce more melanin than 
p53Arg and this p53Pro allele is higher in the equatorial region. Thus, p53Pro form 
protects the individual from solar UV in the Equator by producing more melanin in 
compare with p53Arg form. Thus we hypothesize that p53 polymorphism is naturally 
selected for better survival and ecological adaptation of the individual.  
 
4.3.2  p53Arg allele may predispose to skin cancer 
Human skin is protected from sunlight by the physical barrier of epidermal melanin. 
Because DNA is the central target of solar UV in the skin cells, after solar UV exposure 
p53Pro form protects the cell by producing more melanin and by inducing faster DNA 
repair if any. Conversely, p53Arg containing cells produce less melanin and their DNA 
become affected more than that of p53Pro cells upon UV exposure. Hence, the extent of 
DNA damage in p53Arg cells might be severe than p53Pro cells. Furthermore, reduced 
ability of p53Arg in DNA repair will eventually lead cellular transformation. So, the 
reduced efficiency in DNA repair and melanin synthesis by p53Arg form may explain 
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why high proportion of p53Arg allele has been found in skin cancer in several 
populations (de Oliveira et al., 2004; Chen et al., 2003; O’Conner et al., 2001). 
 
The above information suggests that p53 codon 72 polymophic variants are functionally 
different and they may be selected naturally to maintain genomic integrity.  
 
4.3.3 p53 hotspot mutants along with two polymorphic forms 
Since p53 polymorphism has differential effect on apoptosis and inducing cell cycle 
arrest, drugs that target p53 may have varying effect on individuals with different p53 
genotypes. To understand this, we have investigated the possible role of p53 
polymorphism in response to several anticancer drugs used for cancer therapy using 
isogenic cell lines expressing various p53 hotspot-mutants.  
 
We evaluated the effects of p53 polymorphism and mutations in response to sequential 
treatment with various concentrations of cisplatin followed 24 hours later with a single 
dose of either gemcitabine or etoposide.  
 
This study shows that different p53 mutants respond differently to anti cancer drugs. 
175, 245, 248 and 282 hotspot mutants showed resistant to cisplatin but there was no 
significant difference between p53Pro and p53Arg containing cells. Treatment with 
taxol showed that p53Pro and p53Arg forms responded likewise. However, p53 mutants 
249, 175 and 282 show resistance to doxorubicin, cisplatin + etoposide and cisplatin + 
gemcitabine respectively. The p53Arg mutants tend to show resistance to anticancer 
drugs but this phenomenon depends on the mutation and drug used (Vikhanskaya et al., 
2005). 
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It has been reported that p53Arg mutants are able to inhibit p73-mediated cellular 
transformation compared with p53Pro mutants in human osteosarcoma (SAOS-2) cells 
(Marin et al., 2000; Strano et al., 2000). However, we have observed that both p53Arg- 
and p53Pro-derived mutants equally inhibited p73-mediated transcriptional activity in 
the human lung cancer cell line (H1299) used (Vikhanskaya et al., 2005). This suggests 
that the drug resistance conferred by p53Arg mutants is probably occurred by p73-
independent pathway. Until now the significance of this polymorphism along with 
different mutation is not clear. The various p53 hot-spots also tend to have different 
functional properties and hence, a specific drug may not be applicable for all types of 
tumors with different p53 mutations. Thus, the resistance to anti cancer drugs by p53 
mutants may not be universal and it may depend on the types of mutation and drugs 
along with p53 codon 72 polymorphic forms. As such, these observations require more 
systematic studies of the various p53 mutations with respect to therapeutic response in 
different cell types. 
 
To understand this interesting phenomenon, in vivo study can be done with transgenic 
mouse models that express human p53 codon 72 polymorphic forms along with 
different p53 mutations. In such study, several important properties of p53 mutants in 
response to chemotherapeutic drugs can be studied, such as: effect of a particular drug 
to a particular tissue or organ, response of different p53 mutants to different drugs in 
vivo, and mechanism of drug resistance by different p53 mutants along with 
polymorphism.  
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Chapter 5. Conclusion 
The distribution of p53 polymorphs in Singaporean and Caucasian population showed 
that this polymorphism in different ethnic group is naturally selected which is similar to 
the findings of other investigators. This study supports the findings that frequency of 
p53Pro is higher near the Equator while p53Arg is predominant in the European 
population. In this study, the interesting finding is the differential expression of p53 
alleles in the heterozygotes (p53Arg/p53Pro) in Asian and European population; in both 
populations, the heterozygotes tend to express the dominant allele in the respective 
population. Asian heterozygote population tends to express p53Pro allele whereas 
European heterozygotes express mostly p53Arg allele. These data suggest that there is a 
strong selection pressure on the expression of the alleles in the heterozygotes in these 
two different populations. Although the two polymorphic variants are wild type, they 
may have differential role in maintaining genomic integrity. Expression of p53Arg in 
Singaporean population may not be advantageous and because of this heterozygotes 
may tend to express p53Pro allele. However, p53Pro allele may not be essential in 
Caucasians and hence it has been observed that expression as well as genotype 
frequency of p53Arg in that population are significantly higher. Study on breast cancer 
population in Singapore supports this hypothesis. The presence of large number p53Arg 
in breast tumour population raised the possibility that individuals with p53Arg/Arg or 
p53 Arg/Pro expressing p53Arg allele, are more susceptible to breast cancer, at least in 
Singaporean Chinese population. Analyses of p53 mutation in this population also 
support this hypothesis. 69% tumours with p53Arg do not carry any mutation, while 
55% of p53Pro tumours carry mutation in p53 gene. Furthermore, most of the mutations 
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in p53Arg are outside of the DNA binding domain that are considered recessive 
mutation. While 92% of the p53Pro form carry mutation in the DNA binding domain. 
These suggest that p53Arg is a weaker variant, at least in our study population, to 
prevent breast tumour. 
 
To explain the implication of these two p53 polymorphic variants in cancer 
susceptibility, DNA repair capacity was assed by several methods. Expression study of 
p53-regulated DNA repair genes shows that there is a subtle difference between the 
transactivation potential of these two p53 polymorphic variants. As a result, it has been 
observed that the DNA repair rate is affected and p53Arg form repairs slower than 
p53Pro. The weaker DNA repair capacity by p53Arg was consistent and confirmed by 
several experiments. Because p53 is the main cellular gatekeeper and several important 
pathways that maintain genomic integrity are controlled by p53, this slightly slower 
response of p53Arg form to induce DNA repair could be a causative factor to several 
abnormalities that can cause cellular transformation.  
 
To further explore the functional property of p53 codon 72 polymorphism, their role in 
ecological adaptation was assessed. Since p53Pro is predominant in the equatorial 
region, it can be predicted that this p53 polymorphism may have a role in ecological 
adaptation. Individuals in Equator need more melanin to absorb solar UV to protect 
them from UV-induced DNA damage. Therefore, the individual with dark complexion 
(more melanin) will adapt better in the equatorial region than individual with fair skin. 
However, melanin synthesis is a complex process and multiple factors are involved. In 
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this study, we have observed that p53Pro form has an association with dark complexion, 
which is also reported in several studies and we have observed that melanin synthesis is 
relatively higher in p53Pro expressing cells than the p53Arg counterparts. Based on the 
association between melanin contents and p53 codon 72 polymorphism, it raises the 
possibility that in abundance of sunlight, individual with p53Pro form may adapt better 
than p53Arg form by producing more melanin in the skin.  
 
We have investigated whether this polymorphism is a diagnostic factor in cancer 
treatment. Study on p53 hotspot mutants along with polymorphism and their response to 
cancer therapeutic drugs shows that this p53 polymorphism affects the sensitivity of 
cells to chemotherapeutic drugs. p53 polymorphic status in conjunction with mutations 
affect cellular response to several drugs, such as, cisplatin, etoposide, gemcitabine, 
vinblastine, taxol, and doxorubicin. Cells expressing the 175, 245, 248, and 282 hotspot 
mutations showed varying levels of resistance to cisplatin. Some p53Arg mutants are 
refractory to combination drug treatment. After treating with cisplatin followed by 
gemcitabine cells expressing the 273-p53Arg and 282-p53Arg mutants showed a 
significant antagonistic effect to the combination of drugs. By contrast, there was a 
clear additive effect in cells expressing the p53Pro forms of these mutations.  
 
The findings suggest that p53 codon 72 polymorphic variants may be functionally 
different and this may be a diagnostic factor in cancer therapy. Different types of cancer 
with different p53 polymorphic forms and mutations may require different doses of 
therapeutic drugs. In vivo study on p53 mutants along with polymorphism can give 
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better understanding that can be useful to treat cancer, especially the aggressive 
tumours.  
 
Finally, the studies presented here demonstrates that there are differences between these 
two polymorphic forms of p53, both in terms of expression in healthy and cancer 
patients as well as gene regulation, observed during DNA repair. This study could 
contribute to future analysis for differences between these two polymorphic forms and 
also in understanding the mechanisms operating to bring about these differences.  We 
hope that these findings would form the basis for future in vivo research focusing 
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ppendix II. FACS analysis of cell death after treating 249-p53Pro-, 249-p53Arg- 
nd vector- expressing cell lines with doxorubicin.  
nnexin V and propidium iodide 





























Percentages of apoptotic cells were determined by A
st
 165
